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The organic cation transporters (OCTs) play a critical role in the absorption, 
distribution and elimination of many drugs, hormones, herbal medicines, and 
environmental toxins. Given the broad substrate specificity of OCTs, they fall victim to the 
high susceptibility for contributing to harmful drug-drug interactions. Further defining how 
human (h)OCTs mechanistically bind to its broad array of substrates will provide 
significant insight to the understanding and prediction of drug-drug interactions in 
polypharmacy patients and the advancement of future rational drug design for 
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therapeutics targeting OCTs. The goal of the current study was to elucidate the critical 
amino acid residues for transporter-substrate binding interactions on human (h)OCT1 and 
2 utilizing in silico molecular modeling techniques (homology modeling and automated 
docking), as well as in vitro mutagenesis and kinetic transport experiments.  
Three-dimensional homology models were generated for hOCT1 and 2 using 
Piriformospora indica phosphate transporter (PiPT) serving as template. A putative 
binding pocket was identified and used to dock the prototypical substrate MPP+. Docking 
studies revealed five residues for each transporter (hOCT1 and hOCT2) that may be 
critical for substrate-transporter interactions. The in silico data was used to guide 
subsequent in vitro site-directed mutagenesis and kinetic analysis. Four hOCT1 mutants 
(Gln241Lys, Thr245Lys, Tyr361Ala, and Glu447Lys) and three hOCT2 mutants 
(Gln242Lys, Tyr362Phe, and Tyr362Ala) showed complete loss of MPP+ transporter 
activity. Decreased affinity for MPP+ was observed for Phe244Ser and Thr245Ser in 
hOCT1, and Tyr245Ala in hOCT2. All amino acid residues highlighted in the in vitro 
experiments may be potentially critical for substrate-transporter interactions particularly 
Tyr361, Phe244 and Thr245 in hOCT1; and Tyr362 and Tyr245 in hOCT2. Docking of 
known structurally divergent hOCT1 and hOCT2 substrates revealed similar binding 
interactions as that identified for MPP+, albeit with some unique residues, suggesting the 
presence of a large central cavity within both transporters.  
Through the combination of in silico and in vitro experiments, a putative binding 
pocket was defined and several residues important for substrate-transporter interaction 
were identified and verified for hOCT1 and hOCT2. Further defining how OCTs 
biochemically interact with their broad array of substrates will provide significant insight 
 
 
xvi 
 
to the understanding and prediction of drug-drug interactions in polypharmacy patients 
and the advancement of future rational drug design for therapeutics targeting OCT1 and 
OCT2.  
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CHAPTER 1 
 
OVERVIEW OF EXPRESSION AND FUNCTION OF ORGANIC CATION AND ANION 
TRANSPORTERS 
 
Adapted from manuscript published in Journal of Food and Drug Analysis. (2018) 2: 
S45-S60 [1] 
 
1.A SOLUTE CARRIER 22 TRANSPORTER FAMILY 
Almost a quarter century has passed since the cloning of the first member of what 
is now recognized as the Solute Carrier 22 (SLC22) organic cation/anion/zwitterion 
transporter family. Currently, the Human Genome Organization Gene Nomenclature 
Committee recognizes some 50 SLC families (http://www.genenames.org/cgi-
bin/genefamilies/set/752) with the SLC22 family containing 23 proposed members. The 
SLC22 family includes the organic anion transporters (OATs), organic cation transporters 
(OCTs) and organic cation/carnitine transporters (OCTNs) [2]. Eight members are 
extensively understood in terms of transport function, substrate specificity and driving 
forces; OCT1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3), OAT1 (SLC22A6), OAT2 
(SLC22A7), OAT3 (SLC22A8), OAT4 (SLC22A11) and urate transporter 1 (URAT1, 
SLC22A12). While SLC22 family members are expressed in virtually every barrier 
membrane within the human body (including the blood-testis barrier, blood-brain barrier, 
blood-cerebrospinal fluid barrier, and various CNS cell types), expression and function in 
kidney, liver and intestine has received the most attention (Figure 1.1).  
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Structurally, members of the SLC22 family are proposed to have 12 membrane-
spanning alpha helical domains, a large extracellular glycosylated loop between 
transmembrane domains (TMD) 1 and 2, a large intracellular loop between TMDs 6 and 
7, and intracellular N and C-terminal domains [3] (predicted secondary structure of SLC22 
family transporters shown in Figure 1.2). Within the large loop between the first and 
second TMDs, three N-linked glycosylation sites are present which are proposed to serve 
a variety of functions including protein stabilization, intracellular trafficking, and 
extracellular protease protection [4]. Six sulfhydryl groups (conserved cysteine residues) 
are also present which are theorized as mediators for forming ionic salt bridges which 
help stabilize the three dimensional loop structure critical for transporter oligomerization 
[3–5]. SLC22 family transporters are known to be polyspecific, in other words, they have 
the ability to translocate a variety of structurally diverse small molecules and can be 
inhibited by numerous other compounds [6–9]. Transporters within a given subtype 
commonly share a similar group of preferred substrates and inhibitors, as well as their 
mechanism of transport. 
OCT and OAT substrates cover a wide array of chemical structures and classes 
including pharmacological agents (e.g., morphine, tamoxifen, metformin, cimetidine, 
penicillin G, furosemide, adefovir, cidofovir, indomethacin), neurotransmitters and their 
metabolites (e.g., dopamine, serotonin, homovanillic acid), hormones (e.g., 
prostaglandins, estrone sulfate), environmental toxins/pollutants (e.g., paraquat, 1-
methyl-4-phenylpyridinium, ochratoxin A) and active components found in herbal 
preparations (e.g., lithospermic acid, rosmarinic acid, rhein). 
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Experiments with renal membrane vesicles, tissue slices and intact tubules 
demonstrated that the inside negative membrane potential of a cell drives the uptake 
(cellular entry) of organic cations [10]. That is, cellular entry of organic cations mediated 
by SLC22 family members involves facilitated diffusion, which is ‘powered’ by the 
membrane potential difference and chemical gradient (Figure 1.3). The driving force for 
cellular exit mediated by this transport system was found to be a three-step process 
ending in organic cation/proton (H+) exchange [10]. Initially, Na+/K+-ATPase directly 
hydrolyzes ATP and pumps Na+ out of the cell to establish an inwardly directed Na+ 
gradient, which is subsequently used by Na+/H+ exchanger 3 to establish an inwardly 
directed H+ gradient, that ultimately serves to power cellular exit of organic cations via an 
organic cation/H+ antiporter (Figure 1.3). 
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Figure 1.1 Prominent human SLC22 family members expressed in intestine, kidney 
and liver.  
 
Representative depictions of a human enterocyte, hepatocyte and renal proximal tubular 
cell indicating SLC22 transporters expressed in each tissue and their plasma membrane 
localization.  
 
Figure taken from reference [1]. 
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Figure 1.2 Predicted secondary structure of SLC22 transporters. 
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Figure 1.3 Model depicting driving forces for SLC22 family members.  
Mechanisms/driving forces utilized for cellular entry and exit on the ‘classical’ organic 
cation and organic anion transport systems, using renal proximal tubule cell as an 
example.  
 
Figure taken from reference [1]. 
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For organic anions, cellular entry mediated by SLC22 family members requires 
energy input to drive their movement against the membrane potential (Figure 2). 
Experiments utilizing the above-mentioned systems demonstrated that uptake was 
coupled to established ion gradients (e.g., Na+, α-ketoglutarate) and not to direct ATP 
hydrolysis [10]. That is, cellular entry of organic anions mediated by SLC22 family 
members is driven by a three step process (similar to exit of organic cations) in which 
Na+/K+-ATPase establishes the inwardly directed Na+ gradient, the Na+/dicarboxylate 
symporter 3 utilizes the movement of Na+ ions down their concentration gradient (into the 
cell) to power entry of α–ketoglutarate into the cell (maintaining an outwardly directed 
gradient) and, finally, an organic anion/dicarboxylate antiporter mediates organic anion 
uptake in exchange for α–ketoglutarate [10]. Evidence supports cellular exit via this 
transport system occurring either by facilitated diffusion (using the membrane potential 
as driving force) or anion exchange (antiport) [10].  
A brief synopsis of the discovery of the well-characterized family members is 
presented below, for additional detail see [11–14]. For the purposes of this dissertation, 
subsequent discussion and experimental focus will be on human OCT1, OCT2, and 
OCT3. 
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1.B MAJOR ORGANIC CATION AND ANION TRANSPORTERS 
OCT1 (SLC22A1). First isolated from rat kidney in 1994, orthologs have been 
identified in mouse and human (as well as other species) [15–17]. In humans, OCT1 
expression has been conclusively reported in enterocytes and hepatocytes [15,18]. Rat 
Oct1 transport function correlated with changes in membrane potential, but not proton 
gradient manipulations, indicating OCT1 is driven by facilitated diffusion [17]. Protein 
expression in rats was subsequently confirmed by immunocytochemistry in renal proximal 
tubules and hepatocytes [19,20]. 
OCT2 (SLC22A2). Isolated in 1996 from rat kidney, orthologs have been identified 
in mouse and human (as well as other species) [15,21,22]. In humans, significant OCT2 
expression has been reported in kidney, as well as in the CNS compartment [15,23–25]. 
Rat Oct2 transport function was ablated by membrane depolarization or a trans-applied 
proton gradient, indicating it is also driven by facilitated diffusion [26]. Renal expression 
and basolateral membrane targeting in intact rat proximal tubules was observed [27,28]. 
OCT3 (SLC22A3). Initially cloned from rat placenta [29], mouse and human 
orthologs (as well as other species) have been identified [30,31]. OCT3 appears to have 
the widest tissue distribution among the SLC22 family, including liver, kidney and intestine 
in humans [24,29,30]. Rat Oct3 function was demonstrated to be sensitive to changes in 
membrane potential indicating that it also is a facilitated diffusion carrier [29].  
OAT1 (SLC22A6). Isolated in 1997 from rat kidney [32,33], orthologs have been 
identified in mouse and human (as well as additional species) [34–36]. OAT1 is expressed 
in kidney of all three species, but not in intestine or liver [25,33–35]. Renal expression 
and basolateral membrane targeting in isolated proximal tubules and human and rat 
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kidney was observed [37–39]. Mechanistic examination of rat Oct1 transport function 
demonstrated it is an organic anion/dicarboxylate exchanger [33]. 
OAT2 (SLC22A7). OAT2 was initially cloned from rat liver [40] and human and 
murine orthologs have been isolated [41,42]. Expression of OAT2 in kidney and liver, but 
not intestine, has been detected in mouse, rat and human [43,58,60,61]. OAT2-mediated 
uptake was characterized as being insensitive to trans-stimulation by dicarboxylates 
leading to the interpretation it likely operates via facilitated diffusion [45]. However, 
mechanistically, this would be inconsistent with its postulated role as an uptake carrier.  
OAT3 (SLC22A8). OAT3 was first isolated from rat [46] with mouse and human 
(as well as other species) orthologs identified [47,48]. OAT3 expression has been 
observed in human kidney, but not liver or intestine [47]. Hepatic expression was reported 
in rats, but not mice [44,48]. Immunohistochemistry yielded signal for OAT3 in rat and 
human renal proximal tubules [37,38]. Exploration of OAT3 transport energetics identified 
Na+-dependent trans-stimulation by glutarate indicating that it is driven by organic 
anion/dicarboxylate exchange [49]. 
OAT4 (SLC22A11). OAT4 was discovered in human kidney and placenta [25,50]. 
No additional orthologs or tissues of expression have been identified. Immunodetection 
in proximal tubules has been observed [51]. However, OAT4’s precise mechanism of 
action remains unclear as it has been reported to be a facilitated-diffusion carrier [50], an 
organic anion/dicarboxylate exchanger [52], and a urate/OH- exchanger [53]. 
URAT1 (SLC22A12). Originally isolated from mouse kidney, with rat and human 
orthologs subsequently identified [54–56]. Expression of URAT1 appears to be kidney 
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specific [55,56]. Characterization of URAT1-mediated transport indicated it functions as 
an organic anion/urate exchanger, however, tested dicarboxylates failed to inhibit [55,56]. 
Three key factors needed to most accurately define each individual SLC22 
transporter’s contribution to the transepithelial flux of substrate molecules in each tissue 
are (i) individual transporter affinities for each compound, i.e., Km, Ki, IC50, (ii) the 
concentration of each compound in the systemic circulation, and (iii) absolute SLC22 
protein expression levels in each tissue, ideally in both normal and disease states. Robust 
affinity data are relatively easy to come by using in vitro expression systems of which a 
great deal already exists (Table 1.1). Limited clinical systemic concentration information 
is available in the literature (Table 1.2), however, interpretation of these data should be 
approached with caution at this time due to the use of non-standardized dosage forms 
and inconsistent amounts of individual compounds administered in each study. Thus, 
more formalized clinical studies that administer actual marketed products are required to 
obtain relevant, product-specific (unbound) Cmax values for each compound. Within this 
framework, organ-specific SLC22 protein expression data will further enhance our ability 
to accurately predict their impact on the absorption/flux of drugs, herbal supplement 
components and endogenous compounds. Toward this end, advances in liquid 
chromatography/tandem mass spectrometry methodology have begun to yield 
preliminary data regarding ‘normal’ human transporter expression levels in native cell 
membranes (summarized for SLC22 transporters in Table 1.3). 
Future studies quantifying transporter expression levels in patients suffering from 
acute and chronic disease appear essential (e.g. renal or hepatic failure), as recent 
studies using rat models of ischemia/reperfusion injury and chronic renal failure have 
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demonstrated dramatic changes in SLC22 transporter expression levels. A common 
theme to all of these studies was a significant (~50-85%) downregulation of Oat1 and 
Oat3, and in one instance Oct2, protein expression in rat kidney as determined by 
immunoblotting [57–62]. When examined, this downregulation of SLC22 expression 
correlated with decreased renal clearance of Oat1 and Oat3 substrates [57,58,61]. For 
example, in the ischemia/reperfusion model, significant accumulation of endogenous 
indoxyl sulfate in the systemic circulation was observed beginning at 6 hours post injury 
and the concentration of administered famotidine (20 mg/kg), a substrate for both OCTs 
and OATs, was significantly elevated compared to control rats [58,59]. Thus, quantifying 
transporter protein levels under conditions of organ dysfunction/insufficiency should 
substantially improve modeling and prediction of compound distribution in such patients. 
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Table 1.1 Example compound interactions associated with SLC22 transporters. 
        Kinetics (µM)   
Perpetrator Victim substrateb Transporter
c Cell Typed Km IC50 Ki Reference 
Aloe-emodin 6-CF hOAT1 MDCK  2.29  [63]  
6-CF hOAT3 HEK293  5.37  [63] 
Chrysophanol 6-CF hOAT1 MDCK  >10   [63] 
6-CF hOAT3 HEK293  >10   [63] 
Cisplatin  hOCT2 HEK293 11   [64] 
CMPFa  hOAT1 HEK293 141   [65] 
 hOAT3 HEK293 27   [65] 
Diclofenac Adefovir hOAT1 CHO  4  [66] 
Diflunisal Adefovir hOAT1 CHO  0.85  [66] 
Emodin 6-CF hOAT1 MDCK  0.61  [63] 
6-CF hOAT3 HEK293  1.22  [63] 
Ethambutol MPP+ hOCT1 HEK293  93  [67] 
MPP+ hOCT2 HEK293  254  [67] 
 MPP+ hOCT3 HEK293  4100  [67] 
Etodolac Adefovir hOAT1 CHO  50  [66] 
Flurbiprofen Adefovir hOAT1 CHO  1.5  [66] 
Gallic acid PAH hOAT1 CHO  1.2 1.1 [68] 
ES hOAT3 HEK293  9 8.4 [68] 
Ibuprofen Adefovir hOAT1 CHO  8  [66] 
Indomethacin Adefovir hOAT1 CHO  3  [66] 
Indoxyl sulfate  hOAT1 HEK293 21   [65] 
 hOAT3 HEK293 263   [65] 
Ketoprofen Adefovir hOAT1 CHO  1.3  [66] 
Lithospermic acid PAH hOAT1 CHO   20.8 [69] 
ES hOAT3 HEK293   0.59 [69] 
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PAH mOat1 CHO   14.9 [69] 
ES mOat3 CHO   31.1 [69] 
Nadolol  hOCT2 HEK293 122   [70] 
Naproxen Adefovir hOAT1 CHO  5.8  [66] 
p-cresyl sulfate  hOAT1 HEK293 128     [71] 
  hOAT3 HEK293 >5000     [71] 
Phenacetin Adefovir hOAT1 CHO  200  [66] 
Physcion 6-CF hOAT1 MDCK  > 10   [63] 
 6-CF hOAT3 HEK293  > 10  [63] 
Piroxicam Adefovir hOAT1 CHO  20.5  [66] 
Rhein 6-CF hOAT1 MDCK  0.23  [63] 
 6-CF hOAT3 HEK293  0.08  [63] 
 
PAH hOAT1 CHO 
 0.077 0.072 [72] 
 
ES hOAT3 CHO 
 0.008 0.008 [72] 
 ES hOAT4 CHO  >100  >100  [72] 
 
PAH mOat1 CHO 
  0.19
8 [72] 
 
ES mOat3 CHO 
  0.21
6 [72] 
Rosmarinic acid PAH hOAT1 CHO   0.35 [69] 
 ES hOAT3 HEK293   0.55 [69] 
 PAH mOat1 CHO   5.5 [69] 
 ES mOat3 CHO   4.3 [69] 
Rosuvastatin ES hOAT3 Xenopus oocytes 7.4 25.7  [73] 
Salvianolic acid A PAH hOAT1 CHO   5.6 [69] 
 ES hOAT3 HEK293   0.16 [69] 
 PAH mOat1 CHO   4.9 [69] 
 ES mOat3 CHO   21.3 [69] 
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Salvianolic acid B PAH hOAT1 CHO   22.2 [69] 
 ES hOAT3 HEK293   19.8 [69] 
 PAH mOat1 CHO   236 [69] 
 ES mOat3 CHO   845 [69] 
Tanshinol PAH hOAT1 CHO   40.4 [69] 
 ES hOAT3 HEK293   8.6 [69] 
 PAH mOat1 CHO   136 [69] 
 ES mOat3 CHO   1940 [69] 
Ursolic Acid ES hOAT3 HEK293   19   [74] 
a CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid   
b 6-CF, 6-Carboxyfluorescein; PAH, p-aminohippurate; ES, estrone sulfate   
c h, human; m, murine    
d MDCK, Madin-Darby canine kidney; HEK293, human embryonic kidney; CHO, Chinese hamster ovary 
 
Table taken from reference [1] 
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Table 1.2 Clinical concentrations of example compounds. 
Compound Mean Cmax (µM)a 
Route of 
Administration Dose Species Reference 
Aloe-emodin 0.29 PO 1.25 mg/kgb Rat [75] 
Cisplatin 0.02-0.03 IV 80 mg/m2 Human [76] 
Chrysophanol 4.7 PO 1.25 mg/kgb Rat [75] 
CMPFc 24.8 - - Human [77] 
Diclofenac 6.6 PO 100 mg Human [78] 
Diflunisal 247.8 PO 500 mg Human [79] 
Emodin 0.14 PO 1.25 mg/kgb Rat [75] 
Ethambutol 22, 4.8-26.9 PO 25 mg/kg, 400 mg  Human [80], [81] 
Etodolac 26.1-57.1 PO 50 mg/kg  Rat [82] 
Flurbiprofen 172.3 PO 100 mg Human [83] 
Gallic acid 0.55 PO 400 mg/kg (40 µg)d  Human [84] 
Ibuprofen 208.4-282.1 PO 800 mg Human [85] 
Indomethicin 3.9-6.7 PO 40 mg, 50 mg Human [86] 
Indoxyl Sulfate 2.5 - - Human [87] 
Ketoprofen 13.8-17.8 PO 100 mg Human [88] 
Lithospermic Acid 55.7 IV 10 mL/kg (0.3 mg/kg)e Rat [89] 
Nadolol 0.17 PO 30 mg Human [90] 
Naproxen 187.1 PO 220 mg Human [91] 
p-cresyl sulfate 425.1 - - Human [87] 
Phenacetin 12.5 PO 900 mg Human [92] 
Physcion 1.7 PO 1.25 mg/kgb Rat [75] 
Piroxicam 1.3 PO 20 mg Human [93] 
Rhein 0.54, 2.6 PO 1.25 mg/kgc, 6 g/kgf Rat [75], [94] 
Rosmarinic acid 317.2 PO 20 g/kg (0.391 mg/g)g Rat [95] 
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 516.2 IV 10 mL/kg (1.86 mg/kg)e Rat [89] 
Rosuvastatin 0.012-0.076 PO 20 mg Human [96] 
Salvianolic acid A 0.28 PO 15 g/kg (37.9 mg/kg)h  Rat [97] 
 66.7 IV 10 mL/kg (0.33 mg/kg)e Rat [89] 
Salvianolic acid B 0.14 PO 15 g/kg (15 mg/kg)h Rat [97] 
 237.9 IV 10 mL/kg (1.714 mg/kg)e Rat [89] 
Tanshinol 781.7 PO 20 g/kg (0.743 mg/g)g Rat [95] 
Ursolic acid 2 PO 0.1 g/kgi Rat [98] 
a Converted to µM from original study 
b Semen Cassiae extract  
c CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid 
d Mang-Guo-Zhi-Ke tablet, value in parenthesis represents amount of compound quantified in dosage form 
e Danshen injection, value in parenthesis represents amount of compound quantified in dosage form 
f Rhubarb extract 
g Denshen-Chuanxiong-Honghua extract; value in parenthesis represents amount of compound quantified in dosage form 
h Jitai tablet; value in parenthesis represents amount of compound quantified in dosage form 
i Folium Eriobotryae effective fraction 
 
Table taken from reference [1] 
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Table 1.3 Absolute native tissue protein expression levels for human SLC22 transporters. 
Transporter Kidneya Livera Intestinea Reference 
OAT1 5.33±1.88 NEb NEb [25] 
OAT2 0.93±0.32 1.91±0.58 NEb [25], [99] 
OAT3 3.50±1.55 NEb NEb [25] 
OAT4 0.52±0.23 NEb NEb [25] 
OCT1 NEb 7.35 ± 3.26, 4.45 ± 1.89 0.50c [99], [100], [101] 
OCT2 7.42±2.84 NEb NEb [25]  
OCT3 NRd NRd 0.10c [101] 
a Data are presented as pmol/mg protein ± SD 
b NE = not expressed in this tissue in humans 
c Values estimated from Figure 4 in reference [101], expressed in ileum only 
d NR = not reported  
 
Table taken from reference [1] 
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Human OCT1, OCT2, and OCT3 share overlapping substrate specificity, which 
may be due to a number of factors including having significant sequence similarity (70% 
identical) and similar two-dimensional structure (12 membrane spanning alpha helices) 
[6]. Strong evidence has shown OCTs bind to hundreds of clinically important 
compounds, and as a result of this polyspecificity, their function impacts the 
pharmacokinetic and dynamic effects associated with commonly prescribed medications 
(e.g. cimetidine, metformin), as well as complications arising from drug-drug interactions 
(DDI) [102]. Clinical studies have shown a 1.2-1.7 fold increase in metformin AUC and an 
overall decrease in its renal elimination when co-administered with the OCT2 inhibitors 
cimetidine, trimethoprim, or lansoprazole [103–105]. Similarly, in vivo studies in rats found 
altered pharmacokinetics and decreased elimination of cationic medications were 
associated with downregulation of OCT2 [106,107]. Additional clinical studies have shown 
that OCT1 genetic polymorphisms can also contribute to variations in patient response to 
metformin, particularly its efficacy and distribution [108,109]. Finally, studies utilizing 
OCT3 knockout mice found decreased bioavailability and decreased elimination of orally 
administered metformin [110,111]. Thus, all three OCT paralogs may differentially impact 
the overall pharmacokinetics and efficacy of metformin according to their tissue 
expression and polarity of membrane targeting (Figure 1.1).  
 By virtue of where they are expressed, OCTs have clearly exhibited a strong 
presence in potentiating pharmacokinetic properties of numerous drugs and DDIs. Major 
regulatory agencies, including the U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA), through their guidances strongly suggest the 
importance of in vitro testing of new drug candidates to determine their renal elimination 
 
 
19 
 
and drug-drug interaction potential, specifically emphasizing their interaction likelihood 
with the SLC22 members OCT2, OAT1, and OAT3 [112,113]. From recent discussions 
within the International Transporter Consortium, OCT1, is an emerging clinically important 
transporter that soon could be included in the guidances due to an increasing number of 
studies showing strong associations between OCT1 polymorphisms and pharmacokinetic 
and pharmacodynamic drug effects [114–119]. As such, conducting additional 
pharmacogenomic studies may be strongly advised for new drugs that are substrates of 
OCT1, particularly those with narrow therapeutic windows. It would not be surprising to 
soon see OCT3 added to this list as well. 
Despite this broad evidence supporting the significance of the role of OCT1, OCT2, 
and OCT3 in the translocation of scores of endogenous and exogenous compounds, little 
to nothing is known regarding the biochemical nature of the interactions between known 
substrates/inhibitors and the transporters. In order to establish a strong predictive model 
for DDIs and optimize drug delivery while minimizing harmful side effects for novel drug 
candidates in the pharmaceutical pipeline, identifying the three-dimensional structure, 
substrate-binding pocket, as well as the critical amino acid residues involved in OCT-
substrate interactions is paramount [120]. The most direct method to achieve this overall 
objective is through the utilization of x-ray crystallography. However, to date, only a limited 
number of membrane bound proteins have been successfully crystallized, none of which 
includes any members of the SLC22 family [121]. Therefore, it is of utmost importance to 
resort to alternative approaches. To that end, the construction and application of 
homology models that are based on the experimentally determined high resolution 
structure of related proteins has served as a promising option for characterizing 
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transporter structural properties, substrate-transporter interactions, and mechanisms of 
substrate translocation [121–123].  
1.C CURRENT SCOPE OF MOLECULAR MODELING 
Initial attempts to understand the nature of transporter-substrate interactions for 
organic cation transporters were initially performed on rat Oct1 and Oct2 [124,125]. 
Preliminary knowledge of secondary structure derived from hydropathy sequence 
analysis was used in conjunction with identified evolutionarily conserved amino acid 
regions and amino acid physicochemical properties, in order to identify potential critical 
regions for ligand binding [124,125]. Since OCT ligands carry a positive charge, acidic 
amino acids in these regions were targeted. For example, the aspartic acid at position 
475, located in TMD 11, which is conserved in OCTs, but not OATs, was subjected to 
mutagenesis resulting in changes in rat (r)Oct1 transport activity and suggesting its 
potential significance as an important binding site [124]. Follow up studies were 
performed to determine the amino acids responsible for the higher affinity of the steroid 
hormone, corticosterone, for rOct2 compared with rOct1 [126,127]. Through a series of 
mutations involving the exchange of amino acids between the two paralogs and the 
measurement of different transporter properties, amino acids that may be critical for 
substrate-transporter interactions were identified (Table 1.5) [125]. Thus, what specifically 
distinguishes the OCT paralogs in terms of substrate affinity and/or specificity may be 
related to amino acid differences in these critical regions.  
Despite some apparent success utilizing 2-D models as the basis for establishing 
potential critical binding residues, a significant limitation was the inability to determine the 
binding pockets for substrate-transporter interaction. This limitation can be addressed 
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through the use of more advanced technologies such as X-ray crystallography and NMR. 
However, these methods also have their own limitations such as requiring pure sample 
preparations in concentrations significantly higher than how much they normally appear 
in their natural system. For using NMR to determine protein structure, there also exists 
the hurdle of size limitation, with current technology only being able to process protein 
masses up to 15 kD [128]. Nevertheless, obtaining such structural knowledge can be 
extremely useful for designing effective and safe therapeutic medications [122], 
understanding disease caused by protein polymorphisms [129], as well as optimizing the 
process of elucidating the biochemical interactions of proteins [128].  
Comparative or homology modeling has gained traction in bridging the gap 
between sequence and structural space, as it allows investigators to obtain a reasonable 
prediction of the tertiary structure for proteins that are difficult to crystallize or for which 
structure determination via experimental methods like NMR is not feasible. Homology 
modeling relies on the basis that two proteins that are evolutionarily similar in sequence 
also exhibit analogous structures [130]. The protein with the known structure serves as 
the template for the construction of a model for the protein for which the tertiary structure 
is not known. According to Protein Data Bank [131], the repository of experimental 
structures, the total number of experimental protein structures available to date has 
reached 83,975, however, the rate at which structures are solved experimentally is still 
outpaced by the rate at which new proteins are discovered [132]. This fact adds enhanced 
emphasis to the importance of utilizing homology modeling as a technique that can assist 
in the drug discovery process by aiding the study of the biochemical basis of ligand-
protein interactions, providing novel insight to processes impacting substrate specificity, 
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as well as elucidating structure-function relationships [122]. The degree of structural 
insight provided by homology modeling relies heavily on the degree of sequence similarity 
between the template and target protein [133]. In general, models derived by sequence 
identities > 30% are deemed homologous and presumed to share a common 3-D 
structure based on their evolutionary divergence [134]. Models based on sequence 
identities of 25-50% are considered sufficient for informing site-directed mutagenesis 
experiments, and those >50% are considered reliable for structure-based drug design, 
while sequence identities below 15% are considered suspect for structural modeling 
[134]. The basic steps for homology modeling includes the following: template selection, 
template-target alignment, model building, and model evaluation [135]. This process has 
more recently been coupled with molecular docking in order to optimize models for 
protein-ligand interaction studies as well as structure-based drug design [136].  
Template selection begins through the utilization of a sequence search program 
(e.g. BLAST). Interestingly, although sharing >40% sequence similarity is considered a 
reasonable template for most target proteins, many SLC family members share the same 
secondary structure (same number of folds) in spite of their low overall sequence 
similarity (~10%) [137]. Next, the template and target protein sequences are aligned 
based on their evolutionarily conserved regions by the commonly used program ClustalX 
[138]. Sources of dissimilarity may be due to the presence of large exposed loops 
between transmembrane domains. For optimal homology modeling, especially for 
challenging targets like SLC22s, it is thus important to visually inspect the results, remove 
such loop sequences, and perform any necessary manual adjustments to minimize the 
gaps in the sequence [135]. Once the template-target alignment is generated, 3-D model 
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building is initiated based on the template protein structure. The frequently used program, 
MODELLER (University of California at San Francisco, San Francisco, CA) [139], 
depends on satisfaction of spatial and stereochemical constraints derived from the 
template structure guided by the template-target alignment [123]. The top ranked models 
are then subjected to careful visual inspection to refine errors caused by target-template 
sequence divergence of the top-ranked models and validated using a variety of different 
methods. Such validation methods include the evaluation of stereochemical properties 
(e.g. PROCHECK) [140] and the environment of each amino acid in the model with 
respect to the environment found in experimentally determined structures (e.g. Z-DOPE) 
[141]. Membrane transporters in general pose several challenges for homology modeling 
given their diverse transmembrane secondary structure profiles and their relatively low 
sequence identities/similarities to related solved crystal structures [135]. 
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Table 1.4. Summary of the SLC family homology model template recommendationsa. 
Family Template transporter 
Name Function 
SLC7 AdiC Amino acid antiporter 
SLC10 ASBTNM Apical sodium-dependent bile acid transporter 
SLC15 PepTSO Peptide transporter 
SLC22 High-affinity phosphate importer PiPT Organic cation/anion/zwitterion transporters 
SLC28 vcCNT Concentrative nucleoside transporter 
SLC47 NorM Multidrug and toxin extrusion (MATE) transporters 
a Table adapted from reference [142] 
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Two transporters, derived from Escherichia coli (E. coli), that were successfully 
crystallized, lactose permease transporter (LacY, PDB ID: 1PV6) and glycerol-3-
phosphate transporter (GlpT, PDB ID: 1PW4) have been used previously to homology 
model rat Oct1, rabbit Oct1 and Oct2, and human OCT2 [143–146]. Transport activity for 
MPP+ and TEA was measured in mutants of 18 consecutive amino acids in TMD 4 of rat 
Oct1 [143]. The rationale behind the mutation strategy was based on the fact that TMD4 
contains amino acids on one side of the presumed alpha helix that are conserved within 
the three paralogs of OCTs, but not the OATs. The changes observed in transport activity 
of MPP+ and TEA identified three amino acid residues (Tyr218, Tyr222, and Thr226) 
critical in a proposed binding pocket (Table 1.5). Subsequent homology modeling using 
LacY as template appeared to support this contention [143]. Similarly, in a different study, 
markedly different affinities for selected substrates between rabbit Oct1 and Oct2 were 
demonstrated through site directed mutational studies [145]. Glu447 was found to exert 
a marked influence for substrate selectivity in rabbit Oct2. This result was consistent with 
a subsequently constructed inward open 3-D homology model derived from GlpT, which 
showed Glu447 residing in a hydrophilic cleft of the putative docking region of rabbit Oct2 
[145,147]. An additional study was conducted showing that substitutions at Cys451 
decreased rabbit Oct1 affinity for choline, which was later shown to reside in the choline 
binding domain of a LacY derived homology model [148]. Another group further studied 
human OCT2 and tested the interaction potential of several homologous conserved 
cysteine residues found within TMD 10 and 11 that were theorized to comprise the 
hydrophilic binding cleft [146]. A 3-D homology model was generated for human OCT2 
using GlpT as template to help validate their findings showing that Cys474 serves to form 
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a transport pathway for the OCT2 substrate TEA [146]. Notably, these studies utilized 
homology modeling in an attempt to correlate their mutational study results rather than 
using homology modeling and docking to drive the mutational studies. Amino acid 
residues deemed critical for substrate-binding resulting from these initial tertiary structure-
based modeling studies are summarized in Table 1.5. 
  
 27 
 
 
 
Table 1.5 Summary of critical residues discovered through initial OCT modeling studies.   
Transportera Topology Model Template Critical residue Substrate Reference 
rOct1 2-D - Asp475 (TMD11) MPP+ [124] 
rOct1 2-D - Ile443, Leu447, Gln448 (TMD 10) MPP+, TEA, Corticosterone [125] 
rOct2 2-D - Ile443, Tyr447, Glu448 (TMD 10) MPP+, TEA, Corticosterone [125] 
rOct1 3-D LacY Tyr218, Tyr222, Thre226 (TMD 4) TEA [143] 
rbOct1 3-D LacY Cys451 (TMD 10) Choline [144] 
rbOct2 3-D GlpT Glu447 (TMD 10) TEA [145] 
hOCT2 3-D GlpT Cys474 (TMD 4) TEA [146] 
a r, rat; rb, rabbit; h, human     
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While in the aforementioned studies, several potentially important amino acids for 
substrate binding were identified, the relatively low sequence identity of LacY and GlpT 
with the OCTs (~15%) casts strong doubt as to the exact alignment between the target 
and template [134]. A recent comprehensive comparative analysis of key SLC member 
sequences was conducted, resulting in updated recommendations for crystal structure 
templates in SLC homology modeling [142]. As indicated in Table 1.4, a new protein, 
Piriformospora indica phosphate transporter (PiPT) from the major facilitator superfamily 
(MFS) that has recently been crystallized is considered as the best available template for 
OCT homology modeling studies [149]. Piriformospora indica is a eukaryotic endophytic 
fungus that colonizes the roots of several plant species and is involved in enhancing plant 
growth [149]. PiPT has been recently shown to be a high-affinity transporter responsible 
for improving phosphate nutrition levels in the host plant [150]. PiPT, like hOCTs, has 12 
membrane domain spanning alpha helices [149]. There are specific residues at Tyr328 
and Trp320 on TMD 7 of PiPT that are highly conserved in the SLC22 family which 
suggests a shared substrate-binding mechanism using this helix. PiPT possesses higher 
sequence identity with OCTs (~21% identical, 40% similar) than LacY and GlpT, thus 
increasing the confidence for guiding mutagenesis experiments. Furthermore, PiPT is 
derived from a eukaryotic organism making it evolutionarily more related with the 
mammalian OCTs compared to LacY and GlpT which are both derived from a prokaryote 
(E. coli). LacY and GlpT were both crystallized in an inward-open state while PiPT was 
crystallized in the occluded state which adopts a compact helical arrangement around the 
substrate binding site maximizing the possible interactions between the docked ligand 
and proposed transporter interaction pocket [147,149,151]. An important feature that 
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PiPT possesses that is absent in LacY and GlpT is the intracellular loop between TMD 6 
and 7 that is also evolutionarily conserved in OCTs. 
Therefore, given the aforementioned information, it would seem prudent that 
homology modeling studies in hOCTs be considered using the most recently crystallized 
MFS member, PiPT, to elucidate the amino acid residues critical for transporter-substrate 
binding interactions in human OCT1 and OCT2. 
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CHAPTER 2 
 
RESEARCH OBJECTIVES AND SPECIFIC AIMS 
 
2.A  RESEARCH OBJECTIVES AND HYPOTHESIS 
The overarching goal of the current study is to elucidate the critical amino acid 
residues for transporter-substrate binding interactions on human (h)OCT1 and OCT2 
through in silico molecular modeling techniques (homology modeling and automated 
docking), followed by in vitro mutagenesis and kinetic transport experiments. Our 
hypothesis is that through the substitution of hOCT1 and hOCT2 amino acids involved in 
substrate-transporter interactions, identified by in silico homology modeling with 
Piriformospora indica phosphate transporter (PiPT) as template and molecular docking 
studies, a change in affinity (Km) of the transporter to its prototypical substrate MPP+ will 
be produced. 
 
2.B  SPECIFIC AIMS TO ADDRESS HYPOTHESIS 
SPECIFIC AIM 1 
To identify critical amino acid residues for substrate-binding in hOCT1 and hOCT2  
a. An in-silico 3-dimensional (3-D) predictive homology model of hOCT1 and 
hOCT2 will be constructed using Piriformospora indica phosphate 
transporter (PiPT) as the model template. 
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b. Ligand docking studies will be conducted using the organic cation 
transporter model substrate 1-methyl-4-phenylpyridinium (MPP+) to 
determine the putative substrate binding pocket(s) for hOCT1 and hOCT2. 
c. Putative amino acid residues involved in MPP+ substrate-transporter 
interaction will be identified. 
 
SPECIFIC AIM 2 
To confirm the validity of the predicted critical residues associated with hOCT1 and 
hOCT2 substrate recognition determined through 3-D homology modeling and ligand 
docking, a series of steps to examine changes in substrate affinity will be performed 
including: 
a. The introduction of conservative and non-conservative substitutions that 
alter predicted critical amino acid residues using site-directed mutagenesis. 
b. The creation of stably transfected cell lines expressing hOCT1 and hOCT2 
mutants. 
c. Kinetic analysis to determine the affinity of hOCT1 and hOCT2 mutants for 
the prototypical substrate MPP+. 
d. Confirming membrane targeting for hOCT1 and hOCT2 mutants with 
attenuated transport activity (e.g. via immunodetection with Western blots 
or immunocytochemistry). 
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SPECIFIC AIM 3 
To further evaluate the generated in silico hOCT1 and hOCT2 models, substrates 
with disparate structures will be docked to determine the presence of alternative and/or 
additional critical amino acid residues in the binding pocket(s). This will be evaluated by: 
a. Performing additional docking studies using OCT substrates with varying 
structures (e.g. epinephrine, tetrapentylammonium (TPA), serotonin, 
metformin, cimetidine). 
b.  Comparisons of proposed critical amino acid residues mediating 
transporter-substrate interactions across human OCT1, OCT2 (current 
work) and OCT3 (previous work).  
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CHAPTER 3 
 
IDENTIFYING STRUCTURAL ELEMENTS OF HUMAN ORGANIC CATION 
TRANSPORTER 2 (SLC22A2) MEDIATING SUBSTRATE-TRANSPORTER 
INTERACTIONS 
3.A  INTRODUCTION 
Transporters, which have garnered much interest in the field of clinical 
pharmacology and pharmaceutics, are extensively expressed throughout the body. They 
serve a variety of functions that include the uptake and elimination of both endogenous 
and exogenous compounds. One group of transporters that recognize a broad-spectrum 
of small organic compounds with positive charge are the organic cation transporters 
OCT1, OCT2, and OCT3 [6]. These transporters belong to the solute carrier 22 family 
(SLC22) of the major facilitator superfamily (MFS) and share high sequence homology 
[6,152]. The OCTs are proposed to have 12 membrane-spanning alpha helical domains, 
a large extracellular glycosylated loop between transmembrane domains (TMD) 1 and 2, 
a large intracellular loop between TMDs 6 and 7, and intracellular N- and C-terminal 
domains. 
Due to their expression in intestine, liver, and kidney, the OCTs exert significant 
impact on the pharmacokinetic and pharmacodynamic effects relating to the safety and 
efficacy of many common medications, as well as on the resulting complications arising 
from drug-drug interactions. Both the U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) have issued guidance documents recognizing the 
importance of transporter research in the drug development process [112,113]. The 
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guidances define circumstances under which new investigational drugs should be 
evaluated in vitro as potential transporter substrates, to project their drug-drug interaction 
potential, specifically SLC22 family members including OCT2 (SLC22A2), OAT1 
(SLC22A6), and OAT3 (SLC22A7) [112]. OCT1 (SLC22A1) is an emerging clinically 
important transporter under consideration for addition to the guidances. 
Despite the vast literature base detailing the hundreds of different endogenous and 
pharmaceutical substrates and inhibitors associated with OCTs, the biochemical nature 
of their binding interactions has yet to be determined. The approach to better 
understanding the intricacies of drug transport and ultimately optimizing drug delivery and 
elimination while reducing toxicity lies in 1) revealing the structural foundations of the 
substrate binding region(s), 2) understanding how the variety of substrates bind to 
this(ese) region(s), and 3) how substrate binding contributes to its translocation across 
membranes [120]. The simplest and most direct approach to achieving this goal is to 
determine the structure of the transporter-substrate complex through x-ray 
crystallography. However, to date, no crystal structure of any of the OCTs has been 
successfully solved. An alternative strategy involves the construction of a homology 
model using the known crystal structure of a closely related transporter protein. The 
homology model can then be used to dock substrates in silico to identify putative binding 
pocket(s) and critical residues participating in the binding interactions between substrate 
and transporter.  
Previous homology modeling of rabbit Oct1 and Oct2, and human OCT2 based on 
the tertiary structure of the lactose permease (LacY) and glycerol-3-phosphate (GlpT) 
transporters from E. coli has been performed [143,146,148,153]. However, it is important 
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to note that these bacterial transporter templates exhibit extremely low (~15%) sequence 
identity with mammalian (human) OCTs. Generally, sequence identities of 25-50% are 
considered necessary to generate models useful for informing site-directed mutagenesis 
experiments, with sequence identities below 15% considered suspect for structural 
modeling [134]. Recently, the crystal structure of a more closely related MFS member, 
the Piriformospora indica phosphate transporter (PiPT), has been solved [149]. PiPT 
exhibits ~21% sequence identity with human OCT1, OCT2, and OCT3, and, therefore, 
should provide a better template for generating homology models of these transporters.  
Thus, in order to elucidate the critical amino acid residues for transporter-substrate 
binding interactions on hOCT2, a series of in silico and in vitro experiments were 
conducted. Initially, a novel 3-D homology model for hOCT2 was developed using the 
known crystal structure PiPT. The PiPT structure represents the transporter in its 
occluded state, with endogenous ligand bound. The resulting hOCT2 homology model 
was then used to dock the prototypical substrate, MPP+, to identify the binding pocket(s) 
and potential substrate interacting residues located within it. Next, mutant hOCT2 
transporters containing conservative and non-conservative substitutions of interacting 
residues predicted from the generated model were constructed through site-directed 
mutagenesis. Subsequently, cell lines stably expressing the individual mutant hOCT2 
transporters were established and used to conduct kinetic transport assays (saturation 
analysis) to determine any changes in transporter function and affinity (Km) for MPP+.  
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3.B  MATERIAL AND METHODS 
3.B.1  Chemicals and reagents 
Tritiated [3H] MPP+ was purchased from PerkinElmer Life and Analytical Science 
(Waltham, MA) and unlabeled MPP+ was obtained from Sigma-Aldrich (St. Louis, MO). 
Quinine monohydrochloride dihydrate was purchased from Acros Organics (Fair Lawn, 
NJ). Bio-Rad protein assay dye reagent concentrate was purchased from Bio-Rad 
Laboratories, Inc. (Hercules, CA). Specific primers for mutation reactions were purchased 
from Integrated DNA Technologies (IDT; Coralville, IA). QuikChange Lightning Site-
Directed Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA). 
Lipofectamine® 2000 Transfection Reagent and Prolong diamond antifade mountant with 
DAPI was purchased from ThermoFisher Scientific (Waltham, MA). QIAprep spin 
miniprep kit and QIAprep spin midiprep kit [154] were purchased from QIAGEN Inc. 
(Germantown, MD). GoTaq green master mix was purchased from Promega (Madison, 
WI). Opti-Mem reduced serum and Dulbecco’s modified eagle’s medium were purchased 
from Life Technologies (Carlsbad, CA). Abcam plasma membrane protein extraction kit 
(ab65400) was purchased from Abcam (Cambridge, United Kingdom). Rabbit anti-
SLC22A2 polyclonal antibody (GTX46838) was purchased from GeneTex (Irvine, CA), 
anti-rabbit IgG alkaline phosphatase (AP)-linked antibody (7054S) was purchased from 
Cell Signaling Technology (Danvers, MA), goat anti-actin polyclonal antibody (SC-1616), 
donkey anti-goat IgG-AP (sc-2022), goat anti-rabbit IgG- fluorescein isothiocyanate 
(FITC) (SC-2012), and donkey anti-goat IgG-FITC (SC-2024) were purchased from Santa 
Cruz Biotechnology (Dallas, TX). Nitro-blue tetrazolium and 5-bromo-4-chloro-3'-
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indolyphosphate (NBT/BCIP) and complete mini protease inhibitor cocktail tablets were 
purchased from Roche Diagnostics (Mannheim, Germany).  
3.B.2  Homology modeling and docking studies 
The hOCT2 (UniProt ID: O15244) and PiPT (PDB ID: 4J05) sequences were 
obtained from the Universal Protein Resource (UniProt) and PDB, respectively [131,155]. 
Protein sequence alignment of PiPT and hOCT2 was performed with ClustalX and 
followed by sequence curating via loop removal and manual refinement of gaps based on 
the transmembrane domains observed in the PiPT crystal structure and predicted for 
hOCT2 using ICM Browser (Molsoft LLC) and Phobius (Stockholm Bioinformatics 
Center). Amino acid sequence alignment of hOCT2 with the template and subsequent 
generation of a population of 100 homology models were performed using ClustalX 2.1 
and MODELLER v9.17, respectively. Using SYBL-X 2.1, a structural cavity search was 
conducted for each model to identify putative binding pocket(s). The hOCT2 substrates, 
MPP+, epinephrine, serotonin, cimetidine, tetrapentylammonium (TPA) and metformin, 
and inhibitor, quinine, (Figure 3.1) were sketched and energy-minimized using SYBL-X 
2.1 (Tripos Force Field, Gasteiger-Hückle charges distance-dependent dielectric constant 
= 4.0 D/Å) and docked into each of the 100 models within a 15 Å radius of Trp355 (a 
residue present within the identified binding pocket) using GOLD Suite 5.5. A favorable 
model was selected based on the combined MODELLER discrete optimized protein 
energy (DOPE) score, GOLD docking score, and Ramachandran plot results. The DOPE 
score, accounting for spherical and finite shape of the native structures, helps to 
determine the quality of the protein models. The GOLD score evaluates the interactions 
of the docked substrate within the proposed binding pocket(s). Ramachandran plots were 
 
 
38 
 
used to help visualize energetically allowed regions for backbone dihedral angles against 
amino acid residues in the protein structure. A model with more than 90% of amino acids 
located in the favorable regions of a Ramachandran plot is generally considered an 
acceptable model. High resolution images were obtained using PyMOL v1.8.and SYBL-
X-2.1. 
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Figure 3.1 Chemical structures of compounds docked into hOCT2 homology 
models. 
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3.B.3 Bacterial transformation 
Plasmid DNA (pcDNA3-hOCT2) was transformed through the following steps: 
adding 10 ng of DNA to 50 µL of DH5alpha competent cells, incubating on ice for 30 
minutes, and then applying heat shock at 42°C for 20 seconds. The mixture was then 
added to 950 µL of 37°C preheated LB broth and incubated while shaking (225 rpm) at 
37°C for one hour. Afterward, the mixture was plated onto LB agar plates containing 
ampicillin (0.1 mg/mL) and incubated overnight at 37°C. The following day, colonies were 
picked and grown overnight (with shaking at 225 rpm) in LB broth with ampicillin 
(0.1mg/mL) at 37°C. Plasmid DNA extraction was performed using the Qiaprep spin 
miniprep kit according to the manufacturer’s recommendations [154]. Bacterial pellets 
were resuspended and lysed, followed by the use of spin columns to isolate plasmid DNA 
and wash/discard any impurities in the flow through. Eluted plasmid DNA from the column 
was stored at -20°C. Plasmid DNA concentration and purity were determined via UV 
spectrophotometry.  
3.B.4 Point mutation of plasmid DNA 
Synthetic oligonucleotide primers containing the desired DNA mutations were 
designed using the QuikChange Primer Design program (Agilent Technologies) (Table 
3.1). Amino acid substitutions were introduced into the hOCT2 coding sequence via site 
directed mutagenesis (QuikChange Lightning Site-directed Mutagenesis Kit) according to 
the manufacturer's recommendations. The resulting mutant plasmids were transformed 
into XL 10-GOLD ultra-competent cells according to the manufacturer’s protocol and 
plated on LB-agar plates with ampicillin (0.1 mg/mL) and incubated overnight at 37°C. 
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Colonies were picked, purified, and the presence of the desired mutation was then 
confirmed by DNA sequencing. 
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Table 3.1 Primers for hOCT2 site directed mutagenesis. 
Protein residue Direction Mutant oligonucleotide (5'→ 3') 
Gln242Glu Forward GAA CAG TGG GGA TTT TTT ACG AAG TTG CCT ATA CAG TTG G 
 
Reverse CCA ACT GTA TAG GCA ACT TCG TAA AAA ATC CCC ACT GTT C 
Gln242Lys Forward GAA CAG TGG GGA TTT TTT ACA AAG TTG CCT ATA CAG TTG G 
 
Reverse CCA ACT GTA TAG GCA ACT TTG TAA AAA ATC CCC ACT GTT C 
Tyr245Phe Forward TTT TTA CCA AGT TGC CTT TAC AGT TGG GCT CCT GG 
 
Reverse CCA GGA GCC CAA CTG TAA AGG CAA CTT GGT AAA AA 
Tyr245Ala Forward GAT TTT TTA CCA AGT TGC CGC TAC AGT TGG GCT CCT GGT G 
 
Reverse CAC CAG GAG CCC AAC TGT AGC GGC AAC TTG GTA AAA AAT C 
Thr246Ser Forward TTT ACC AAG TTG CCT ATT CAG TTG GGC TCC TGG T 
 
Reverse ACC AGG AGC CCA ACT GAA TAG GCA ACT TGG TAA A 
Thr246Lys Forward GGA TTT TTT ACC AAG TTG CCT ATA AAG TTG GGC TCC TG 
 
Reverse CAG GAG CCC AAC TTT ATA GGC AAC TTG GTA AAA AAT CC 
Tyr362Phe Forward CAC GAG CTC TGT GCT CTT CCA GGG CCT 
 
Reverse AGG CCC TGG AAG AGC ACA GAG CTC GTG 
Tyr362Ala Forward CAC GAG CTC TGT GCT CGC CCA GGG CCT CAT CAT G 
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Reverse CAT GAT GAG GCC CTG GGC GAG CAC AGA GCT CGT G 
Glu448Asp Forward GAT CAC AAT GGC CTA TGA TAT AGT CTG CCT GGT CAA T 
 
Reverse ATT GAC CAG GCA GAC TAT ATC ATA GGC CAT TGT GAT C 
Glu448Ala Forward GAT CAC AAT GGC CTA TGC GAT AGT CTG CCT GGT CA 
  Reverse TGA CCA GGC AGA CTA TCG CAT AGG CCA TTG TGA TC 
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3.B.5 Cell line transfection and maintenance 
Mutant transporter expressing CHO cell lines were generated using cationic lipid-
based transfection. Briefly, 1μg plasmid DNA was combined with 2 µL Lipofectamine 
2000 (Invitrogen), mixed, diluted in 100 µL Opti-MEM (Invitrogen) and applied to CHO 
cells at 50-60% confluency in 12-well plates (Corning Inc, Corning, NY). Fresh culture 
medium (DMEM/F12) was applied just prior to the addition of transfection agents. After 
incubating for 24 hours at 37°C / 5% CO2, the transfection medium was removed and 
replaced with fresh medium containing Geneticin (G418; 1 mg/mL) to select for 
successfully transfected cells for a period of 14-21 days. Cells viable in the presence of 
G418 were transferred to culture flasks and continued to be maintained under antibiotic 
selective pressure (250 µg/mL G418). 
CHO control, CHO-hOCT2 and CHO-hOCT2 mutant cell lines were maintained in 
Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12) with 10% FBS, and 1% 
Penicillin/Streptomycin at 37°C with 5% CO2 in 25 or 75mm2 polystyrene flasks. G418 
(250μg/mL) was included in the medium for maintaining selective pressure on stably-
transfected cell lines. Cells were sub-cultured every 3-4 days and passages 10-40 were 
used for experiments. 
3.B.6 Cell accumulation assays 
 Mutant functional screening 
The procedure for the cell accumulation assay has been described previously 
[68,69]. Briefly, cells were seeded into 24-well tissue culture plates at a density of 1.5×105 
cells/well in the absence of antibiotics and cultured for 48 hours. Cells were equilibrated 
with transport buffer for 10 min (500 µL of Hanks’ balanced salt solution containing  
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10 mM HEPEs, pH 7.4). Equilibration transport buffer was replaced with 400 µL of fresh 
transport buffer containing 1 µM unlabeled MPP+ spiked with trace [3H]MPP+ (0.25 µCi/ml) 
in the presence or absence of the inhibitor quinine (200 µM). After incubation for 10 
minutes, the cells were immediately rinsed 3 times with ice cold transport buffer, lysed 
with 200 µL 1N NaOH, neutralized with 250 µL 1N HCl and 200 µL 10mM HEPES. The 
radioactivity in cell lysates was quantified by liquid scintillation counting, and uptake 
normalized by the total protein content determined by the Bradford method. The 
intracellular accumulation of substrates was reported as picomoles of substrate per 
milligram total protein. All uptake data were corrected for background accumulation in 
corresponding CHO empty vector cells.  
Kinetic assays 
The Michaelis-Menten constant (Km) was determined for MPP+ uptake in each of 
the generated mutant hOCT2-expressing cell lines via saturation analysis according to 
our established protocol [156]. The experiment was carried out in the same way as 
described for the functional screening assay with the exception that the equilibration 
transport buffer was replaced with 400 µL of fresh transporter buffer containing increasing 
concentrations (1-200 µM) of unlabeled MPP+ spiked with [3H]MPP+ (0.25 µCi/ml) and 
incubated for a period of 1 minute. After incubation, the cells were immediately rinsed 3 
times with ice cold transport buffer and lysed with 1N NaOH, neutralized with 250 µL 1N 
HCl and 200 µL 20mM HEPES. The Km estimate, which represents the concentration of 
substrate at half maximum velocity of the transporter, was calculated using nonlinear 
regression with the enzyme kinetics model in GraphPad Prism 5.0 (GraphPad Software 
Inc., San Diego, CA). Individual saturation experiments were repeated at least three times 
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with duplicate wells and plotted as mean ± SD. Km estimates were reported as mean ± 
SE.  
3.B.7 Genomic DNA integration confirmation 
Cells were suspended in 500 μL lysis buffer [1 M Tris (pH 8.0), 5 M NaCl, 0.5 M 
EDTA, and 10% SDS] containing proteinase K (0.4 mg/mL) and incubated at 55°C while 
shaking overnight. Genomic DNA was thoroughly extracted from samples with an equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) after gentle mixing for 10 min, and 
centrifugation for 10 min at 15,000 g. The upper aqueous phase was carefully collected, 
isopropanol was added and mixed well, then centrifuged immediately at 15,000 g for 30 
min to obtain DNA pellet. The pellet was washed with 70% ethanol, dried, and 
resuspended with 50 µL TE buffer [10 mM Tris (pH 8.0), and 1 mM EDTA]. Concentration 
of DNA was determined through UV spectrophotometry. Genomic DNA (2 ng), 2x Go-taq 
Master Mix (5 μL), as well as 1 μL primer pair mix (T7: 5’- TAATACGACTCACTATAGGG-
3; hOCT2-REV: 5’- CCAGTGAGGAAGTGCGTAAG -3’) were added together to a final 
volume of 20 µL and run in a thermocycler: initial denaturation at 95°C for 5 min, followed 
by 30 cycles of: denaturation at 95°C for 2 min, annealing at 50-52°C for 30 seconds, and 
elongation at 72°C for 30 seconds. Final elongation step at 72°C for 5 min and held at 
4°C. PCR products were loaded into a 1% agarose gel for separation using 
electrophoresis at 120 V for 60 min and visualized by UV light following ethidium bromide 
staining. 
3.B.8 Cell harvest for immunoblotting 
Cell lines were harvested according to the Abcam plasma membrane extraction kit 
protocol (Abcam, Cambridge, United Kingdom): Briefly, cells were removed by scraping 
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in phosphate buffered saline (PBS, Gibco/Invitrogen), centrifuged for 5 minutes at 700 x 
g, washed with ice cold PBS, then resuspended with the homogenization buffer and 
mixed with a Dounce homogenizer on ice. Afterward, the homogenate was centrifuged at 
700 x g for 10 minutes at 4°C. The supernatant was collected and transferred to a new 
vial and centrifuged at 10,000 x g for 30 minutes at 4°C. Supernatant (cytosolic fraction) 
was collected and stored at -80°C.  
3.B.9 SDS-PAGE and Immunoblotting 
The cytosolic and plasma membrane fractions were harvested according to the 
plasma membrane extraction kit protocol (Abcam). Protein concentration was quantified 
using the Bradford method. Samples (20 µg) were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) using the Bio-Rad Mini-PROTEAN 
system. Samples were separated using 12% polyacrylamide gels at 170V for 1.5 hours 
and then transferred onto polyvinylidene difluoride (PVDF) membrane (Bio-Rad, 
Hercules, CA) for 1 hour at 100 mA. Membranes were blocked with 5% BSA in TBST (19 
mM Tris base, 137 mM NaCl, 2.7 mM KCl, 0.05% Tween 20, 0.05% sodium azide) for 1 
hour. The rabbit anti-OCT2 polyclonal antibody was diluted (1:400) to 2.5 µg/mL in 5% 
BSA and the blots probed overnight at 4°C with rocking (18 hours). Three 5-minute 
washes were performed with TBST then alkaline phosphatase conjugated secondary 
antibody diluted (1:1000) in 5% BSA was added and incubated for 2 hours at room 
temperature with rocking. Blots were washed three times for 5 minutes with TBST before 
being developed in 0.1 M Tris, 0.1 M NaCl, 5mM MgCl2 phosphatase buffer (pH 9.4) 
containing 0.25 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP, Sigma-Aldrich) and 
 
 
48 
 
0.25 mg/ml nitro blue tetrazolium (NBT, Sigma-Aldrich) in the dark. Blots were digitally 
scanned. 
3.B.10  Immunocytochemistry  
Cells were prepared for immunostaining by plating 6 x 104 cells/ml onto flame 
sterilized 12 mm cover slips (Fisher Scientific) in 6-well plates (Corning, Inc.) overnight in 
the absence of antibiotics. Cells (~70% confluent) were washed with PBS, fixed with 4% 
paraformaldehyde in PBS for 10 minutes, and permeabilized with 0.01% TritonX in PBS. 
The cells were then washed with 1x PBS followed by blocking with 1% BSA in 1x PBS for 
1 hour at room temperature. The rabbit anti-OCT2 primary antibody was diluted (1:100) 
with 1% BSA in TBST and incubated with the cells at room temperature for 1 hour. Cells 
were washed three times for 5 minutes with PBS. FITC anti-rabbit secondary antibody 
was diluted to (1:100) in 1% BSA in TBSTA and applied to the cells for 1 hour at room 
temperature in the dark. Cells were washed three times for 5 minutes with PBS, placed 
on slides with DAPI prolong diamond mounting media and imaged with a fluorescence 
microscope (Olympus I51, Olympus, upper Saucon Township, PA). 
3.B.11  Green fluorescent protein (GFP) plasmid construction 
To make the hOCT2-GFP fusion construct, the full length hOCT2 cDNA fragment 
was removed from the isolated library clone, pcDNA3/hOCT2, using the restriction 
enzymes Kpn I and Xba I. The fragment was gel isolated and ligated into the pEGFP-C1 
vector in frame at the carboxyl terminal end of GFP forming the plasmid pEGFP-
C1/hOCT2, where “E” denotes “enhanced”. Plasmid construction was performed 
commercially (GenScript, Picataway, NJ). The lyophilized GFP plasmid construct, was 
resuspended and diluted in TE pH 8, transformed into DH5-alpha cells and DNA extracted 
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using the Qiagen miniprep kit. The construct was confirmed by DNA sequencing. Non-
functional hOCT2 mutants were reproduced in the hOCT2-GFP construct using the 
original primers (Table 3.1) and the QuikChange Lightning site-directed mutagenesis kit. 
3.B.12  Microscopic imaging  
An Olympus IX-70 inverted microscope fit with a 12-bit camera (Olympus, Melville, 
NY) was used in order to capture phase contrast and fluorescent images. Fluorescent 
images were taken with two second exposures using a 595 nm dichroic long pass filter 
(Chroma, Rockingham, VT) illuminated by a mercury arc lamp. The images were 
processed using Olympus Microsuite v.5. Confocal fluorescent images were obtained at 
the VCU Microscope Core facility using a Zeiss LSM 710 Axio Observer inverted laser 
scanning confocal microscope fit with a 63x oil immersion objective. Images were 
collected by illuminating samples with a blue diode laser at 405 nm. Images were 
processed using Zeiss ZEN 2 Blue edition software (Oberkochen, Germany). 
3.B.13  Statistics 
The data plots were presented as means ± SD. Dose response curve (Km estimate) 
data were reported as mean ± SE for at least n = 3. Km estimates were fit based on the 
equation: V0 = Vmax * [S] / (Km + [S]). One-way ANOVA with post-hoc Dunnett’s test was 
used to evaluate differences compared to a single control where indicated. Statistical 
calculations were performed using Prism 5.0 (GraphPad Software, Inc., San Diego, CA). 
A difference was deemed statistically significant if p < 0.05. 
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3.C RESULTS 
3.C.1 Identification of a hOCT2 model 
The hOCT2 peptide sequence (Uniprot ID: O15244) was aligned with the PiPT 
template sequence (PDB ID: 4J05) (Figure 3.2) as input for the program MODELLER to 
generate 100 initial hOCT2 homology models. Analysis of the initial 100 models identified 
a single large cavity in the central region of the transporter as a potential binding pocket. 
MPP+ was subsequently docked in this region. After docking MPP+ into the generated 
hOCT2 models, the most favorable interaction model was selected based on three main 
criteria: GOLD docking score, DOPE score, and the total number of clusters. 
The genetic optimized ligand docking (GOLD) scoring is essentially a method to 
quantify which poses generated for a particular ligand are most likely to occur based on 
the interactions present within the transporter. GOLD scores for the top ten most 
favorable docked poses of MPP+ in the binding pocket of the hOCT2 models (ranging 
from 58.49 to 66.59) were ranked (Table 3.2). Amongst this select group, the top three 
model’s GOLD scores had a difference of 0.77 between them, thus were considered to 
be virtually identical. The difference between the top and fourth ranked model was 
increasingly larger (1.61). The discrete optimized protein energy (DOPE) score accounts 
for the shape of native structures which in turn helps to evaluate the quality of the whole 
protein structure. The DOPE scores for the top ten models ranged between -48,186 and  
-47,268 (Table 3.2). Additionally, the number of homology models which contained a 
given substrate pose (number of clusters) was also accounted for in model selection. The 
greater the number of models that have a particular substrate pose docked, the higher 
the likelihood that the specific pose occurs within the binding pocket.  Out of the top 10 
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models, models 30 and 64 had 6 clusters, while the rest had 4 or less. Among the top 
three ranked GOLD score models, model 64 stood out as having the lowest DOPE score 
(-48,030; second lowest DOPE score overall) in conjunction with the highest number of 
clusters (6). Taken together, these three selection criteria indicated model 64 as the most 
favorable docked model and thus it was selected for subsequent studies. The generated 
tertiary structure for model 64 with MPP+ docked in the hypothesized binding pocket is 
shown in Figure 3.3. The docked hOCT2 model shows MPP+ residing inside a large 
central cavity of the 12-membrane spanning alpha helical domains (Figure 3.3). 
Ramachandran plots were utilized as a method for determining and visualizing 
“allowed regions” for the backbone dihedral angles that make up amino acids in the 
generated model. For the amino acids that made up our selected hOCT2 model, 91.4% 
were in the most favored regions, 6.1% were in the additionally allowed region, and only 
2.4% were in the generously allowed and disallowed regions combined (Figure 3.4). The 
most favored regions category was > 90%, thus supporting the selected hOCT2 model 
as acceptable. 
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Figure 3.2 Sequence alignment of PiPT and hOCT2.  
 
The alignment was constructed with ClustalX, followed by manually refining gaps based 
on the transmembrane regions observed in the PiPT crystal structure and predicted for 
hOCT2 using Phobius, a topology prediction algorithm. Residues forming the large 
extracellular and intracellular loop between transmembrane domain 1 and 2 and 
intracellular loop between 6 and 7 of PiPT and hOCT2. The transmembrane domains in 
the hOCT2 model (red) and PiPT tertiary structure (blue) are highlighted. “*” indicates 
exact sequence match, “:” indicates high sequence similarity, “.” indicates low sequence 
similarity 
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Table 3.2 Summary of hOCT2 model evaluation scores. 
GOLD Rank Model ID Gold score DOPE Score 
No. of 
Clusters 
1 24 66.59 -47676.04688 2 
2 12 66.52 -47487.76953 2 
3 64 65.82 -48030.84375 6 
4 47 64.98 -47691.90625 3 
5 2 64.1 -47665.14453 1 
6 30 62.73 -47813.59766 6 
7 95 61.53 -47268.98438 4 
8 100 60.53 -48186.85547 3 
9 55 59.64 -47915.82422 4 
10 71 58.49 -47584.00781 1 
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Figure 3.3 hOCT2 homology model. 
 
The generated 3-D molecular structure of hOCT2 (ribbons) is shown with MPP+ (space-filled) positioned in the putative 
binding pocket viewed from (A) profile and (B) top-down angles.  
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Figure 3.4 Ramachandran plot for hOCT2 homology model. 
Phi and psi indicate backbone conformation dihedral angles of amino acid residues, 
representing the rotations of a polypeptide main chain N-Cα and Cα-C bonds. Amino 
acids are displayed in different regions: most favored region (red), additional allowed 
region (yellow), generously allowed region (light yellow), and disallowed region (white). 
Residues depicted in red squares are in the generously allowed and disallowed regions. 
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3.C.2 Identifying amino acid residues important for MPP+ hOCT2 interaction 
Several amino acids were identified that made up the binding pocket (within the 
designated 5 Å radius of the substrate) for docked MPP+ in the selected hOCT2 model. 
The identified amino acid residues were found in several different TMDs that came 
together in the central area forming a large distinct cavity of the transporter—TMD 1: 
Phe17; TMD 5: Ile239, Gln242, Val243, Tyr245, Thr246, Val247, Leu249; TMD 7: Trp355, 
Ser358, Ser359, Tyr362, Gln363, Gln387; TMD 8: Gln387, Phe388, Ala391, Ile394; TMD 
10: Trp407, Met445, Ala446, Tyr447, Glu448, Val450, Cys451 (Figure 3.5). Within the 
proposed binding pocket, five amino acids were identified (Gln242, Tyr245, Thr246, 
Tyr362, and Glu448) as potential candidates critical for transporter-MPP+ binding 
interactions. Hydrophobic interactions were found between MPP+ and amino acid 
residues Gln242, Thr246, and Glu448, and one of the aromatic rings of MPP+ was 
recognized as forming edge-face-pi and pi-stacking interactions with Tyr245 and Tyr362, 
respectively (Figure 3.6 and Table 3.3).  
To further evaluate the generated in silico hOCT2 model, known substrates with 
disparate structures were optimized and docked into the population of 100 models to 
determine the presence of alternative and/or additional critical amino acid residues in the 
binding pocket(s). The process involved with selecting the most favorable model for 
MPP+, was repeated for each docked substrate. Amino acids identified with the greatest 
overlap across the different docked compounds were Tyr245, Ser358, Tyr362, and 
Glu448 (Figure 3.7 and Table 3.3). There were several amino acids identified that were 
also unique to particular compounds including Thr246 for MPP+; Gln363, Gln387 and 
Cys451, for serotonin; Cys474 for TPA; and Asp475 for cimetidine.  
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Figure 3.5 3-D rendering of putative binding pocket of hOCT2 with docked MPP+. 
Amino acid side chains (white) comprising the binding pocket surrounding the substrate MPP+ (orange) is shown viewed 
from (A) profile and (B) top-down angles. 
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Figure 3.6 Structure of hOCT2 with MPP+ docked. 
 
The docked substrate (MPP+, orange) and the amino acids (white side chains) is shown 
localized in the predicted substrate binding pocket of hOCT2.  
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Table 3.3 hOCT2 docking interaction summary. 
Substrate Amino Acid Sequence position Bond Interaction TMD 
MPP+ Gln 242 Hydrophobic 5 
Tyr 245 Hydrophobic/Edge-Face Pi 5 
Thr 246 Hydrophobic 5 
Tyr 362 Pi-stack 7 
Glu 448 Hydrophobic 10 
Cimetidine Asn 157 H-bond 2 
 
Tyr 245 Hydrophobic 5 
 
Ser 358 H-bond 7 
 
Tyr 362 Pi-stacking 7 
 
Glu 448 H-bond (salt bridge) 10 
  Asp 475 H-bond (salt bridge) 11  
Epinephrine Tyr 245 Hydrophobic 5 
 
Ser 358 H-bond 7 
 
Tyr 362 Pi-stack 7 
  Glu 448 H-bond (salt bridge) 10 
Metformin Ser 358 H-bond 7 
 
Tyr 362 Pi-stack 7 
  Glu 448 H-bond (salt bridge) 10 
Quinine Phe 24 Hydrophobic 1 
 
Asn 157 H-bond (weak) 2 
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Phe 160 Hydrophobic 2 
 
Gln 242 H-bond 5 
 
Tyr 245 Hydrophobic 5 
  Tyr 362 Pi-stacking 7 
Serotonin Tyr 245 Hydrophobic 5 
 
Ser 358 H-bond 7 
 
Tyr 362 Pi-stack 7 
 
Gln 363 H-bond 7 
 
Glu 387 H-bond (salt bridge) 8 
 
Glu 448 H-bond (salt bridge) 10 
  Cys 451 H-bond 10 
TPA Phe 24 Hydrophobic 1 
 
Phe 160 Hydrophobic 2 
 
Tyr 245 Hydrophobic 5 
  Cys  474 Hydrophobic 11 
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Figure 3.7 Known hOCT2 substrates docked into hOCT2 homology model. 
Known hOCT2 substrates (purple or orange) (A) cimetidine, (B) epinephrine, (C) metformin, (D) quinine, (E) serotonin, and 
(F) TPA, were docked into their respective favorable hOCT2 models. Proposed interactions of interactions are summarized 
in Table 3.3. 
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3.C.3 Substitution of hOCT2 amino acid residues in putative binding pocket 
We investigated the role of the predicted amino acids in hOCT2-MPP+ interactions 
through conservative and non-conservative amino acid substitutions introduced into the 
hOCT2 coding sequence to evaluate potential changes in hOCT2 function and affinity for 
MPP+. The pcDNA3/hOCT2 plasmid vector map is shown in Figure 3.8. The rationale for 
deciding each conservative and non-conservative amino acid substitution was based on 
a scheme developed by Bordo et al. which categorizes roughly equivalent amino acid 
residues based on their physicochemical properties of their side chains (Figure 3.9) [157]. 
Substitutions for residues deemed critical were Gln242Glu, Tyr245Phe, Thr246Ser, 
Tyr362Phe, and Glu448Asp (conservative); and Gln242Lys, Tyr245Ala, Thre246Lys, 
Tyr362Ala, and Glu448Ala (non-conservative) (Tables 3.4, 3.5 and 3.6). All hOCT2 
mutants were confirmed by DNA sequencing prior to generating stable cell lines. Figure 
3.10, depicts a representative DNA-oligonucleotide duplex and sequencing 
chromatogram in which TAC, coding for Tyr362 in wildtype hOCT2, was changed to TTC, 
coding for the hOCT2 mutant Tyr362Phe. 
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Figure 3.8 pcDNA3/hOCT2 vector map. 
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Figure 3.9 Suggested guidance for amino acid residue conservative substitution. 
Roughly equivalent amino acid residues categorized based on physiochemical properties into five subgroups.  
 
Diagram is an adapted figure from reference [157]  
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Table 3.4 Summary of hOCT2 residue substitutions. 
  Substitution 
Residue Conservative Non-Conservative 
Gln242 Glu Lys 
Tyr245 Phe Ala 
Thr246 Ser Lys 
Tyr362 Phe Ala 
Glu448 Asp Ala 
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Table 3.5 hOCT2-MPP+ interaction based conservative substitutions. 
Amino Acid Sequence position Codon Mutant Codon Substitution 
Gln 242 CAA GAA Gln → Glu 
Tyr 245 TAT TTT Tyr → Phe 
Thr 246 ACA TCA Thr → Ser 
Tyr 362 TAC TTC Tyr → Phe 
Glu 448 GAG GAC Glu → Asp 
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Table 3.6 hOCT2-MPP+ interaction based non-conservative substitutions. 
Amino Acid Sequence position Codon Mutant Codon Substitution 
Gln 242 CAA AAA Gln → Lys 
Tyr 245 TAT GCT Tyr → Ala 
Thr 246 ACA AAA Thr → Lys 
Tyr 362 TAC GCC Tyr → Ala 
Glu 448 GAG GCG Glu → Ala 
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Figure 3.10 Representative sequencing chromatogram for hOCT2 mutants. 
(A) DNA template-primer duplex for hOCT2 Y362F. Chromatogram for (B) hOCT2 
wildtype and (C) hOCT2 Y362F are shown with triplet codon corresponding to mutation 
site highlighted. 
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3.C.4 Critical amino acid confirmation through kinetic assays 
In functional screening assays evaluating [3H] MPP+ transport (Figure 3.11), wild-
type hOCT2 demonstrated a 4.5-fold higher uptake of MPP+ compared to mock 
expressing (pcDNA3) background control cells (15.7 ± 0.4 pmol mg protein-1 10 min-1 vs. 
3.5 ± 2.7 pmol mg protein-1 10 min-1). Quinine (200 µM), a known inhibitor for OCTs, 
virtually abolished hOCT2 mediated MPP+ transport. Two non-conservative mutants, 
hOCT2 Glu242Lys and Tyr362Ala, and one conservative mutant, hOCT2 Tyr362Phe, 
resulted in a complete loss of MPP+ transport activity (Figure 3.11). All other mutants 
retained some level of transport activity and were subjected to saturation analysis in order 
to estimate Km (Figure 3.12, Table 3.7).  
The affinity of MPP+ determined for wildtype hOCT2 was comparable to values in 
prior studies (Km = 19.7 ± 3.4) [158]. When comparing the Km estimates for hOCT2 
mutants against wildtype hOCT2, only the non-conservative substitution Tyr245Ala 
resulted in a significant change in affinity for MPP+. The mutants Gln242Glu, Tyr245Phe, 
Thr246Ser, Thr246Lys, Glu448Asp, Glu448Ala, and Asp475Glu all demonstrated no 
significant change in affinity for MPP+.  
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Figure 3.11 Functional screen of CHO-hOCT2 wild type and mutant expressing cell 
lines. 
 
CHO cells were treated with transport buffer containing 1 µM [3H] MPP+ (0.25 µCi/mL) in 
the absence or presence of inhibitor (quinine) for 10 min. Conservative and non-
conservative mutations appear above original amino acid position. Data shown as 
duplicate wells ± SD. ** denotes p<0.01; *** denotes p<0.001; compared against wild type 
control by one-way ANOVA followed by post-hoc Dunnett’s t-test.  
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Figure 3.12 Representative dose response curves for wild type and mutant hOCT2. 
Michaelis-Menten kinetics of [3H] MPP+ transport (1–200 µM) for hOCT2 and hOCT2 
mutants in stably transfected CHO cells.  
 
  
 
 
72 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.7 Summary of Km estimates for hOCT2 constructs. 
hOCT2 Transporter Km (µM)  
WT  19.7 ± 3.4 
Gln242Glu 31.9 ± 6.2 
Tyr245Phe 22 ± 7.5 
Tyr245Ala 36.5 ± 5* 
Thr246Ser 15.5 ± 2.8 
Thr246Lys 27.4 ± 12.3 
Glu448Asp 17.9 ± 3.6 
Glu448Ala 17.2 ± 3.8 
Asp475Glu 13.5 ± 4 
Mean Km estimates acquired from at least 3 experiments ± SE. 
* denotes p < 0.05 compared against wild type control by one-
way ANOVA followed by post-hoc Dunnett’s t-test. 
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3.C.5 Genomic integration of non-functional hOCT2 mutant constructs 
To eliminate failed genomic DNA integration as an explanation for the lack of 
transport activity in non-functional hOCT2 mutants, genomic DNA was extracted and PCR 
amplified using the primers T7 and hOCT2 REV, that flanked 5’ and 3’ ends of the hOCT2 
coding sequence of the pcDNA3 plasmid (hOCT2 amplicon ~1.8 kb). PCR products of 
the expected size (~1.8 kb) were obtained for wildtype hOCT2 and all hOCT2 mutants 
(Gln242Lys, Tyr362Phe, and Tyr362Ala), while no product was observed for negative 
controls (water and pcDNA3) demonstrating that all hOCT2 plasmids had been 
successfully integrated (Figure 3.13).  
3.C.6 Immunodetection of non-functional hOCT2 mutants 
To investigate the translation and membrane targeting for hOCT2 mutants that 
failed to demonstrate MPP+ transport, Western blotting was performed on isolated 
cytoplasmic and plasma membrane fractions from each mutant-expressing cell line using 
hOCT2 polyclonal antibody (Figure 3.14). Protein bands were observed at the expected 
position for wildtype hOCT2 (~62 kD), however, a similar band was also seen for CHO 
empty vector membrane fraction. Detection for β-actin was consistently observed (~43 
kD) in all experiments (Figure 3.14). 
An alternative method for evaluating membrane targeting of non-functional hOCT2 
mutants was pursued. The same antibodies used to probe for hOCT2 in earlier Western 
blot studies were also used for immunocytochemistry experiments. Cells expressing 
wildtype pcDNA3/hOCT2 constructs showed strong cytosolic fluorescence for both actin 
and hOCT2 staining, with no detectable signal in the nucleus (Figure 3.15). Strong 
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membrane localization, however, was not present in any of the observed cells. Control 
transfections (lipofectamine only) showed no fluorescent signal (data not shown).  
3.C.7 Membrane targeting of hOCT2-GFP fusion construct 
The full length hOCT2 cDNA fragment was gel isolated and ligated into vector 
pEGFP-C1 forming the plasmid pEGFP-C1/hOCT2 containing hOCT2 fused in frame to 
the carboxyl terminal of GFP (Figure 3.16). CHO cells expressing the hOCT2-GFP fusion 
construct showed strong fluorescence within the cytosol and lack of signal in the nucleus 
(Figure 3.17). This pattern is consistent with an intact GFP fusion construct versus 
expression of “free” GFP. However, no noticeable fluorescence at the plasma membrane 
was observed. Control transfections (lipofectamine only) showed no fluorescent signal 
(data not shown). In order to have a reference of the membrane localization of OCTs, 
MDCK cells stably transfected with a rat Oct2-GFP fusion construct from a previous study 
were grown and observed [159] (Figure 3.18).   
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Figure 3.13 PCR analysis of genomic DNA isolated from hOCT2 cell lines. 
Confirmation of successful genomic integration of mutant hOCT2 constructs that lacked 
transport activity. Lanes: (1) water, (2) pcDNA3, (3) hOCT2, (4) hOCT2 Gln242Lys, (5) 
hOCT2 Tyr362Phe, and (6) hOCT2 Tyr362Ala. 
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Figure 3.14 Western blot of CHO cell lysates probing for hOCT2.  
Lanes: (1) Protein size standard, (2) mock cytosolic fraction, (3) mock membrane fraction, 
(4) hOCT2 cytosolic fraction, (5) hOCT2 membrane fraction.  
†, denotes actin; *, denotes expected hOCT2 size. 
 
 
 
 
 
 
 
 
 
* 
† 
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Figure 3.15 Immunocytochemistry of CHO-hOCT2. 
CHO cells expressing hOCT2 were probed with anti-actin (A) or anti-hOCT2 (B) 
antibodies followed by FITC conjugated secondary antibody and observed under 
fluorescent microscopy (40x magnification).  
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Figure 3.16 pEGFP-C1/hOCT2 fusion protein vector map. 
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Figure 3.17 Expression patterns of pEGFP-C1/hOCT2. 
CHO cells transfected with pEGFP-C1/hOCT2 were fixed, permeabilized, and mounted 
at 24 hours post transfection then viewed under confocal microscopy: (A) phase contrast, 
(B) GFP, (C) DAPI, and (D) merge. Scale bar = 20 µm 
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Figure 3.18 Expression of pEGFP-C3/rOct2 in MDCK cells. 
MDCK cells stably transfected with pEGFP-C3/rOct2 were thawed, grown in culture for 
48 hours, then observed by fluorescence microscopy (40x magnification). Observed cells 
were used in a study performed in reference [159]. 
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3.D DISCUSSION 
The broad structural substrate diversity of the OCTs make them highly susceptible 
sites for potentially harmful drug-drug interactions. Therefore, an increased 
understanding of the biochemical nature of the interactions between transporter and 
substrates could provide a prevailing advantage in improving the prediction of drug 
interactions involving these membrane transporters. Recently, increased efforts have 
been devoted towards better understanding the biochemical interactions between 
transporter and substrate among organic cation transporters [124,125,146,148,153]. 
Several studies utilized hypothesized 3-D structures of their target transporter (e.g. rat 
Oct1, rabbit Oct1 and Oct2, and hOCT2) in order to confirm experimentally predicted 
critical residues [143,146,148,153] (Table 1.5 in Chapter 1). These early studies 
generated homology models of OCTs based on the solved crystal structures of 
prokaryotic MFS transporters (from E. coli). Although the studies provided information on 
the structural details for OCTs that were previously unknown, the templates they used to 
generate models (i.e. LacY, GlpT) were limited in the fact that they share a low sequence 
identity with mammalian (human) OCTs (~15%) perhaps due to their prokaryotic origin.  
Therefore, in the current study, homology models of the tertiary structure of hOCT2 
were generated using the known crystal structure of PiPT serving as the template. PiPT, 
also a member of the MFS, was chosen as the designated template due to a number of 
factors including its relative sequence homology to the hOCTs (~21% identical, 40% 
similar), eukaryotic origin (Piriformospora indica), and the fact that it was crystallized in 
the occluded state. The occluded conformation grants the transporter maximum binding 
interaction sites for bound ligands. After docking MPP+ into the generated hOCT2 models, 
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amino acid residues were identified that formed the putative binding pocket (within a 5 Å 
radius surrounding the substrate) (Figure 3.5). This approach required that several 
assumptions be made during the in silico model building process including that adequate 
structural similarity exists between the crystallized tertiary structure of PiPT and hOCT2 
and that the presence of water molecules in the occluded binding pocket was negligible 
and therefore not considered during the docking analysis.  All models were generated 
based on PiPT and the hOCT2 protein sequence with transmembrane domains globally 
energy minimized.  
Amino acid residues deemed “critical” for hOCT2-MPP+ binding interactions were 
identified in silico based on substrate proximity and interaction types (Table 1.5). Within 
the proposed binding pocket, hydrophobic interactions were identified between MPP+ and 
amino acid residues Gln242, Thr246, and Glu448, and one of the aromatic rings of MPP+ 
was found to be involved in edge-face pi and pi-stacking interactions with Tyr245 and 
Tyr362, respectively. Subsequently, stably transfected CHO cells expressing hOCT2 
mutants were established and utilized for a series of in vitro kinetic assays to confirm their 
role in substrate binding. From the functional screening study, transport activity of MPP+ 
was absent for both conservative and non-conservative substitutions of Tyr362, and for 
the non-conservative substitution of Gln242 (Figure 3.11). Because MPP+ transport was 
lacking for both conservative and non-conservative substitutions at Tyr362, this 
suggested that it may be a critical site for substrate binding. This result correlates with the 
MPP+ docking data where Tyr362 was predicted to participate in the strongest substrate 
interaction (pi-pi stacking). However, the loss of transport activity with the conservative 
phenylalanine substitution, where the only structural difference is a loss of an aromatic 
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hydroxyl group, suggests that the hydroxyl group in Tyr362 may mediate additional 
important interactions with other residues within the binding pocket beyond pi-pi stacking 
with the substrate, thus playing a significant role in forming the structure of the binding 
pocket. When the hydroxyl is absent, as in the Tyr362Phe mutant, the residue may exist 
in a different spatial conformation that makes it less accessible for substrate-pi-stacking 
interactions. For hOCT2 mutants retaining MPP+ transport function, only Tyr245Ala 
demonstrated a significant decrease in affinity for the substrate compared to wildtype 
(Table 3.7). As such, Tyr245 also may be deemed an important site for hOCT2-MPP+ 
interaction. To briefly summarize, these initial findings suggest that Gln242, Tyr245, and 
particularly Tyr362 may be important for hOCT2-MPP+ interactions within the proposed 
binding pocket. Tyr362 demonstrates the strongest case for importance considering both 
its conservative and non-conservative substituted mutants eliminated transporter activity 
for MPP+.  
There are several explanations for the hOCT2 mutants (Gln242Lys, Tyr362Phe, 
and Tyr362Ala) that exhibited complete loss of MPP+ transport activity. The specific 
amino acid may be a critical residue for transporter-MPP+ substrate interactions and thus 
when substituted leads to a complete absence of MPP+ accumulation. Alternatively, the 
proposed transporter-binding pocket conformation could be altered as a result of the 
mutated residue. Another possibility is that transfection was not successful and therefore 
cDNA integration into the genomic DNA would be absent. Finally, the amino acid could 
be critical for maintaining the tertiary and quaternary structure of the transporter and when 
mutated could lead to a misfolded protein that is subsequently degraded rather than 
trafficking to the cell membrane following translation.  
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Genomic integration of intact cDNA for hOCT2 mutants was confirmed by PCR 
and gel electrophoresis (Figure 3.13) which ruled out a failed transfection. In order to 
confirm that inactive mutant hOCT2 transporters were translated and inserted into the 
plasma membranes of transfected mammalian cell lines Western blotting was performed. 
Transporter protein detected in the cell membrane fraction of nonfunctional mutants 
would suggest that the wildtype amino acid is likely a critical residue for interactions with 
MPP+. However, in this study, the polyclonal hOCT2 antibody failed to discriminate 
between CHO mock and hOCT2 transfected cells (Figure 3.14). Additionally, the antibody 
did not appear to bind specifically to hOCT2, as signal was detected at the expected 
position in membranes prepared from CHO mock, as well as from wildtype hOCT1 or 
hOCT3 expressing cells (data not shown). The consistent detection of a clear, single band 
for actin ruled out any issues related to assay technique. When hOCT2 was probed in 
subsequent immunocytochemistry experiments using the same polyclonal hOCT2 
antibody, no consistent fluorescent signal localized in the plasma membrane of CHO cells 
expressing hOCT2 was observed indicating the issue was related to the commercial 
hOCT2 antibody’s lack of specificity. Thus, no conclusions could be drawn from these 
experiments.  
Previous studies successfully demonstrated plasma membrane targeting when the 
transporter sequence for rOct1 or rOct2 was fused in frame to the C-terminus of GFP and 
transfected into MDCK cells [159,160]. A similar approach was performed in the current 
study by fusing the coding sequence of hOCT2 to the C-terminus of GFP to evaluate 
membrane targeting of non-functional hOCT2 mutants. However, we failed to observe 
targeting at the plasma membrane in CHO cells transiently transfected with the wildtype 
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hOCT2-GFP fusion construct. Instead we observed a consistent pattern of fluorescence 
in the cytosol surrounding the nucleus. The discrepancy in what was observed compared 
to the prior studies may be due to differences associated with the cell line used (MDCK 
vs CHO cells). A future study involving the transfection of our pEGFP-hOCT2 fusion 
construct into MDCK cells should be considered.  
In the analysis of docking known substrates with varying structures into the hOCT2 
homology models, interacting amino acids were identified to be unique for some 
substrates and shared for others (Table 3.3). For example, Glu448 was amongst the 
residues identified that was shared across many substrates including MPP+, cimetidine, 
epinephrine, metformin, and serotonin. This residue corresponds to Glu477 in rabbit Oct2, 
which was identified as being critical for mediating TEA transport and verified by a rabbit 
Oct2 homology model based on GlpT [153]. Glu447/Glu448, an amino acid with an acidic 
side chain, may be a critical site for anchoring positively charged substrates under 
physiological conditions. Cys474, which was identified in a prior study as a critical site for 
forming a pathway for hOCT2 mediated TEA transport and confirmed through homology 
models  based on the crystallized structure of LacY [146], was also identified in the 
present study for interacting with TPA. This finding was not too surprising considering the 
shared quaternary nitrogen-based structural scaffold of TEA and TPA. From these 
observations, our model suggests that there may be one binding pocket along the central 
cavity of hOCT2. Within this binding pocket, there may be a core set of amino acids that 
interact with most substrates, in conjunction with additional substrate-specific amino acids 
that accommodate structurally diverse (typically larger) substrates. Additional in vitro work 
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involving transporter mutagenesis experiments and subsequent kinetic analysis for each 
substrate would be necessary to support the preliminary in silico findings. 
Based on the in silico hOCT2 modeling and subsequent in vitro kinetic studies, the 
amino acids most critical for MPP+ interactions reside in TMDs 5, 7 and 10. Prior studies 
based on secondary and tertiary structures identified critical interacting residues in TMDs 
4, 10, and 11 [124,125,143,146,148,153]. There are a number of factors that could 
explain this apparent discrepancy. The majority of the prior substrate interaction studies 
were done with rodent OCTs; thus, species differences could account for the variations 
of identified residues. Additionally, different substrates were examined; TEA and choline 
were used in the rat and rabbit studies whereas the focus of the current work was on 
interactions with MPP+. As revealed in the analysis of docking diverse substrates in the 
current study, critical interacting amino acids may be unique to each substrate. This is not 
a surprising result given the diverse array of structures represented by OCT2 substrates. 
Finally, for the homology studies that have been performed previously, the templates 
utilized (LacY and GlpT) were both crystallized in the inward open conformation. 
Considering that PiPT was crystallized in the occluded state, different amino acids may 
be exposed to the substrates during in silico docking across the two conformation states. 
It may most likely be a combination of the latter two aspects in that structurally diverse 
substrates interact with unique sets of amino acids in a “transport channel” and these also 
vary as the transporter transitions through outward open, occluded, and inward open 
stages during substrate translocation. 
In summary, a homology model for hOCT2 based on an existing crystallized 
structure of PiPT was successfully generated. Amino acid residues that may be critical 
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for hOCT2 transporter-substrate interactions along with a proposed binding pocket region 
were identified based on the selected MPP+ docked model and were probed in vitro 
through mutagenesis studies. Additionally, a study involving the docking of known 
substrates into hOCT2 models identified overlapping and additional residues that may 
mediate transporter binding interactions. The results obtained in our combined in silico 
and in vitro study suggests a single binding region present along a central cavity within 
hOCT2 that shares some similarity with models generated in earlier published work. 
Future work, particularly confirming successful membrane targeting of non-functional 
hOCT2 mutants, will be necessary to strengthen our conclusions. Despite this 
shortcoming, the data acquired in the present study provides a sound foundation for 
understanding the physiochemical nature of hOCT2-substrate interactions that may 
ultimately serve to help optimize future rational drug design.   
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CHAPTER 4 
 
IDENTIFYING STRUCTURAL ELEMENTS OF HUMAN ORGANIC CATION 
TRANSPORTER 1 (SLC22A1) MEDIATING SUBSTRATE-TRANSPORTER 
INTERACTIONS 
 
4.A  INTRODUCTION 
The organic cation transporters (OCTs), OCT1, OCT2, and OCT3, are members 
of the solute carrier 22 (SLC22) subfamily of the major facilitator superfamily and via 
facilitated diffusion are responsible for the cellular entry of a variety of structurally diverse 
small organic molecules typically with positive charge. The OCT paralogs share 
similarities in their sequence, transmembrane topology, preferred substrates, and 
mechanism of substrate translocation. Despite these similarities, their sites of expression 
in the major organ systems vary. In humans, OCT1 and OCT3 both mediate substrate 
entry into enterocytes (OCT1 and OCT are expressed along the basolateral membrane 
and brush border, respectively) [1]. OCT1 and OCT3 are expressed along the sinusoidal 
membrane of hepatocytes in the liver playing a role in the first steps of hepatic elimination 
for their substrates [6]. In kidney, OCT2 and OCT3 are expressed on the basolateral 
membrane of proximal convoluted tubules governing the initial process of renal 
elimination [1]. OCTs have been shown to interact with hundreds of different endogenous 
and exogenous substrates/inhibitors under physiological conditions which include 
metabolites (e.g. creatine), neurotransmitters (e.g. serotonin, dopamine), hormones (e.g. 
 
 
89 
 
corticosterone), receptor antagonists (e.g. cimetidine), and antidiabetics (e.g. metformin) 
[1]. Due to their polyspecific nature and their tissue expression profiles, OCTs play a 
pivotal role in the absorption and elimination of their substrates impacting their 
pharmacokinetics and efficacy. As such, there is an increased potential for drug-drug 
interactions in patients taking concomitant medications. 
OCT2, is an important mediator of renal elimination and also a major site for 
clinically important drug-drug interactions. In turn, OCT2 has been routinely studied 
during the drug development process and is even included in regulatory guidances (e.g. 
FDA and EMA) as a protein target for the evaluation of new drug entities as 
substrates/inhibitors [112,113]. OCT1, on the other hand, despite being expressed in the 
sinusoidal membrane of hepatocytes and potentiating the initial steps of hepatic 
elimination for hundreds of compounds, has only recently emerged as a “clinically 
important” transporter. Evidence has been reported highlighting the significance of OCT1 
in drug-drug interactions and pharmacogenetic variability [116,161,162]. For example, 
fenoterol, a widely used narrow therapeutic window anti-asthmatic drug, was shown to 
have its pharmacokinetics and pharmacodynamics affected by genetic variants of OCT1 
[161]. Compared to healthy individuals, OCT1-deficient patients demonstrated a 1.9-fold 
increase in systemic fenoterol exposure and 1.7-fold decrease in volume of distribution. 
As a result, heart rate and blood glucose both significantly increased by 1.5-fold, and 3.4-
fold, respectively [161]. OCT1 also was shown to mediate hepatic uptake of sumatriptan, 
a drug used to treat acute migraines [116]. Systemic exposure of sumatriptan was 
increased by 2.1-fold in OCT1-deficient patients which was comparable to individuals with 
liver impairment. OCT1 polymorphisms, showed similar pharmacokinetic effects for the 
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active metabolite of the opiate analgesic tramadol, tropisetron, where systemic exposure 
was increased by 2-fold in homozygous OCT1 variant carriers [162]. These studies 
strongly suggest hepatic OCT1 to be a clinically important mediator of pharmacogenetic, 
pharmacokinetic and pharmacodynamic variability, and potentially drug-drug interactions. 
For the aforementioned studies, OCT1 serves as the rate limiting step for the transfer of 
many drugs from the systemic circulation to the liver. As OCT1 governs the hepatic 
clearance of these compounds, it essentially serves to mediate systemic drug exposure, 
thus establishes itself from a mechanistic DDI perspective as a potential major 
determinant of pharmacokinetics and drug clearance [163]. In light of the evidence, 
members of the International Transporter Consortium have even raised strong 
suggestions that evaluations of OCT1 be included as part of a rational drug design 
strategy [163]. 
Having the 3-D structural information available for hOCT1 is paramount for 
obtaining a better understanding of transporter-substrate interactions from a 
physicochemical perspective. However, to date, a crystal structure for any SLC22 family 
member has yet to be solved. An alternative strategy involves the construction of a 
homology model using the known crystal structure of a closely related protein (in this case 
transporter). Earlier studies have used the prokaryotic lactose permease (LacY) and 
glycerol-3-phosphate (GlpT) transporters as templates for studying the structures of 
OCT1 and OCT2 in rat, rabbit, and human [124,127,143,145,146,148] (Table 1.5). 
Despite these efforts identifying a number of amino acid residues that may be critical for 
OCT-substrate interaction, their models were generated based on templates that were 
prokaryotic in origin, crystallized in an inward facing conformation, and shared low OCT 
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sequence similarity (~15%). Additionally, the homology models were generated in order 
to confirm the spatial orientation of important residues identified in vitro, rather than used 
as a preliminary step for guiding amino acid mutational experimentation.  
In the current study, the elucidation of critical amino acid residues for transporter-
substrate binding interactions of hOCT1 was conducted by the generation of homology 
models using the Piriformospora indica phosphate transporter (PiPT), a structurally 
related eukaryotic transporter, as template. The information acquired from the newly 
constructed model was utilized in order to make predictions and assist in facilitating site 
directed mutagenesis studies to assess the homology model’s validity and to observe any 
potential changes in transport function and/or affinity (Km) for its prototypical substrate, 
MPP+. Docking studies for hOCT1 were performed for additional known substrates with 
varying structure in order to more broadly investigate transporter-substrate interaction. 
Further defining how OCT1 biochemically interacts with its broad array of substrates will 
provide significant insight to the understanding and prediction of drug-drug interactions in 
polypharmacy patients and the advancement of future rational drug design for 
therapeutics targeting OCT1. 
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4.B MATERIAL AND METHODS 
4.B.1 Chemicals and reagents 
Tritiated [3H] MPP+ was purchased from PerkinElmer Life and Analytical Science 
(Waltham, MA) and unlabeled MPP+ was obtained from Sigma-Aldrich (St. Louis, MO). 
Quinine monohydrochloride dihydrate was purchased from Acros Organics (Fair Lawn, 
NJ). Bio-Rad protein assay dye reagent concentrate was purchased from Bio-Rad 
Laboratories, Inc. (Hercules, CA). Specific primers for mutation reactions were purchased 
from Integrated DNA Technologies (IDT; Coralville, IA). QuikChange Lightning Site-
Directed Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA). 
Lipofectamine® 2000 Transfection Reagent and Prolong diamond antifade mountant with 
DAPI was purchased from ThermoFisher Scientific (Waltham, MA). QIAprep spin 
miniprep kit and QIAprep spin midiprep kit [154] were purchased from QIAGEN Inc. 
(Germantown, MD). GoTaq green master mix was purchased from Promega (Madison, 
WI). Opti-Mem reduced serum and Dulbecco’s modified eagle’s medium were purchased 
from Life Technologies (Carlsbad, CA).  
4.B.2 Homology modeling and docking studies 
The hOCT1 (UniProt ID: O15245) and PiPT (PDB ID: 4J05) sequences were 
obtained from the Universal Protein Resource (UniProt) and PDB, respectively [131,155]. 
Protein sequence alignment of PiPT and hOCT1 was performed with ClustalX and 
followed by sequence curating via loop removal and manual refinement of gaps based on 
the transmembrane domains observed in the PiPT crystal structure and predicted for 
hOCT1 using ICM Browser (Molsoft LLC) and Phobius (Stockholm Bioinformatics 
Center). Amino acid sequence alignment of hOCT1 with the template and subsequent 
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generation of a population of 100 homology models were performed using ClustalX 2.1 
and MODELLER v9.17, respectively. Using SYBL-X 2.1, a structural cavity search was 
conducted for each model to identify putative binding pocket(s). The hOCT2 substrates, 
MPP+, epinephrine, serotonin, cimetidine, tetrapentylammonium (TPA) and metformin, 
and the hOCT2 inhibitor, quinine, (Figure 4.1) were sketched and energy-minimized using 
SYBL-X 2.1 (Tripos Force Field, Gasteiger-Hückle charges distance-dependent dielectric 
constant = 4.0 D/Å) and docked into each of the 100 models within a 15 Å radius of Trp354 
(a residue present within the identified binding pocket) using GOLD Suite 5.5. A favorable 
model was selected based on the combined MODELLER discrete optimized protein 
energy (DOPE) score, GOLD docking score, and Ramachandran plot results. The DOPE 
score, accounting for spherical and finite shape of the native structures, helps to 
determine the quality of the protein models. The GOLD score evaluates the interactions 
of the docked substrate within the proposed binding pocket(s). Ramachandran plots were 
used to help visualize energetically allowed regions for backbone dihedral angles against 
amino acid residues in the protein structure. A model with more than 90% of amino acids 
located in the favorable regions of a Ramachandran plot is generally considered an 
acceptable model. High resolution images were obtained using PyMOL v1.8.and SYBL-
X-2.1. 
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Figure 4.1 Chemical structures of compounds docked into hOCT1 homology 
models. 
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4.B.3 Bacterial transformation 
Plasmid DNA (pcDNA3-hOCT1) was transformed through the following steps: 
adding 10 ng of DNA to 50 µL of DH5alpha competent cells, incubating on ice for 30 
minutes, and then applying heat shock at 42°C for 20 seconds. The mixture was then 
added to 950 µL of 37°C preheated LB broth and incubated while shaking (225 rpm) at 
37°C for one hour. Afterward, the mixture was plated onto LB agar plates containing 
ampicillin (0.1 mg/mL) and incubated overnight at 37°C. The following day, colonies were 
picked and grown overnight (with shaking at 225 rpm) in LB broth with ampicillin 
(0.1mg/mL) at 37°C. Plasmid DNA extraction was performed using the Qiaprep spin 
miniprep kit according to the manufacturer’s recommendations [154]. Bacterial pellets 
were resuspended and lysed, followed by the use of spin columns to isolate plasmid DNA 
and wash/discard any impurities in the flow through. Eluted plasmid DNA from the column 
was stored at -20°C. Plasmid DNA concentration and purity were determined via UV 
spectrophotometry.  
4.B.4 Point mutation of plasmid DNA 
Synthetic oligonucleotide primers containing the desired DNA mutations were 
designed using the QuikChange Primer Design program (Agilent Technologies) (Table 
4.1). Amino acid substitutions were introduced into the hOCT1 coding sequence via site 
directed mutagenesis (QuikChange Lightning Site-directed Mutagenesis Kit) according to 
the manufacturer's recommendations. The resulting mutant plasmids were transformed 
into XL 10-GOLD ultra-competent cells according to the manufacturer’s protocol and 
plated on LB-agar plates with ampicillin (0.1 mg/mL) and incubated overnight at 37°C. 
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Colonies were picked, purified, and the presence of the desired mutation was then 
confirmed by DNA sequencing. 
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Table 4.1 Primers for hOCT1 site directed mutagenesis. 
Protein residue Direction Mutant oligonucleotide (5' → 3') 
Gln241Glu Forward CCG TGA AGG CCA TCT CGT ACA TGA TCG CCA C 
 
Reverse GTG GCG ATC ATG TAC GAG ATG GCC TTC ACG G 
Gln241Lys Forward CCG TGA AGG CCA TCT TGT ACA TGA TCG CCA C 
 
Reverse GTG GCG ATC ATG TAC AAG ATG GCC TTC ACG G 
Phe244Tyr Forward CAG CCC CAC CGT GTA GGC CAT CTG GTA 
 
Reverse TAC CAG ATG GCC TAC ACG GTG GGG CTG 
Phe244Ser Forward CAG CCC CAC CGT GGA GGC CAT CTG GTA 
 
Reverse TAC CAG ATG GCC TCC ACG GTG GGG CTG 
Thr245Ser Forward CCA GCC CCA CCG AGA AGG CCA TCT G 
 
Reverse CAG ATG GCC TTC TCG GTG GGG CTG G 
Thr245Lys Forward CAG CCC CAC CTT GAA GGC CAT CTG GTA CAT 
 
Reverse ATG TAC CAG ATG GCC TTC AAG GTG GGG CTG 
Tyr361Phe Forward GAG CCC CTG AAA GAG CAC AGA GTC CGT GA 
 
Reverse TCA CGG ACT CTG TGC TCT TTC AGG GGC TC 
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Tyr361Ala Forward CAC GGA CTC TGT GCT CGC TCA GGG GCT CAT CCT G 
 
Reverse CAG GAT GAG CCC CTG AGC GAG CAC AGA GTC CGT G 
Gln447Glu Forward CAC CAG GCA GAT CAT TTC TAT TGC AAT GGT GAT TCC 
 
Reverse GGA ATC ACC ATT GCA ATA GAA ATG ATC TGC CTG GTG 
Gln447Lys Forward TCA CCA GGC AGA TCA TTT TTA TTG CAA TGG TGA TTC CC 
  Reverse GGG AAT CAC CAT TGC AAT AAA AAT GAT CTG CCT GGT GA 
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4.B.5 Cell line transfection and maintenance 
Mutant transporter expressing CHO cell lines were generated using cationic lipid-
based transfection. Briefly, 1μg plasmid DNA was combined with 2 µL Lipofectamine 
2000 (Invitrogen), mixed, diluted in 100 µL Opti-MEM (Invitrogen) and applied to CHO 
cells at 50-60% confluency in 12-well plates (Corning Inc, Corning, NY). Fresh culture 
medium (DMEM/F12) was applied just prior to the addition of transfection agents. After 
incubating for 24 hours at 37°C / 5% CO2, the transfection medium was removed and 
replaced with fresh medium containing geneticin (G418; 1 mg/mL) to select for 
successfully transfected cells for a period of 14-21 days.  
CHO control, CHO-hOCT1 and CHO-hOCT1 mutant cell lines were maintained in 
Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12) with 10% FBS, and 1% 
Penicillin/Streptomycin at 37°C with 5% CO2 in 25 or 75mm2 polystyrene flasks. G418 
(250μg/mL) was included in the medium for maintaining selective pressure on stably-
transfected cell lines. Cells were sub-cultured every 3-4 days and passages 10-40 were 
used for experiments. 
4.B.6 Cell accumulation assays 
 Mutant functional screening 
The procedure for the cell accumulation assay has been described previously 
[68,69]. Briefly, cells were seeded into 24-well tissue culture plates at a density of 1.5×105 
cells/well in the absence of antibiotics and cultured for 48 hours. Cells were equilibrated 
with transport buffer for 10 min (500 µL of Hanks’ balanced salt solution containing 10 
mM HEPEs, pH 7.4). Equilibration transport buffer was replaced with 400 µL of fresh 
transport buffer containing 1 µM unlabeled MPP+ spiked with trace [3H]MPP+ (0.25 µCi/ml) 
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in the presence or absence of the inhibitor quinine (200 µM). After incubation for 10 
minutes, the cells were immediately rinsed 3 times with ice cold transport buffer, lysed 
with 200 µL 1N NaOH, neutralized with 250 µL 1N HCl and 200 µL 10mM HEPES. The 
radioactivity in cell lysates was quantified by liquid scintillation counting, and uptake 
normalized by the total protein content determined by the Bradford method. The 
intracellular accumulation of substrates was reported as picomoles of substrate per 
milligram total protein. All uptake data were corrected for background accumulation in 
corresponding CHO empty vector cells.  
Kinetic assays 
The Michaelis-Menten constant (Km) was determined for MPP+ uptake in each of 
the generated mutant hOCT1-expressing cell lines via saturation analysis according to 
our established protocol [156]. The experiment was carried out in the same way as 
described for the functional screening assay with the exception that the equilibration 
transport buffer was replaced with 400 µL of fresh transporter buffer containing increasing 
concentrations (1-200 µM) of unlabeled MPP+ spiked with [3H]MPP+ (0.25 µCi/ml) and 
incubated for a period of 1 minute. After incubation, the cells were immediately rinsed 3 
times with ice cold transport buffer and lysed with 1N NaOH, neutralized with 250 µL 1N 
HCl and 200 µL 20mM HEPES. The Km estimate, which represents the concentration of 
substrate at half maximum velocity of the transporter, was calculated using nonlinear 
regression with the enzyme kinetics model in GraphPad Prism 5.0 (GraphPad Software 
Inc., San Diego, CA). Individual saturation experiments were repeated at least three times 
with duplicate wells and plotted as mean ± SD. Km estimates were reported as mean ± 
SE. 
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4.B.7  Genomic DNA integration confirmation 
Cells were suspended in 500 μL lysis buffer [1 M Tris (pH 8.0), 5 M NaCl, 0.5 M 
EDTA, and 10% SDS] containing proteinase K (0.4 mg/mL) and incubated at 55°C while 
shaking overnight. Genomic DNA was thoroughly extracted from samples with an equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) after gentle mixing for 10 min, and 
centrifugation for 10 min at 15,000 g. The upper aqueous phase was carefully collected, 
isopropanol was added and mixed well, then centrifuged immediately at 15,000 g for 30 
min to obtain DNA pellet. The pellet was washed with 70% ethanol, dried, and 
resuspended with 50 µL TE buffer [10 mM Tris (pH 8.0), and 1 mM EDTA]. Concentration 
of DNA was determined through UV spectrophotometry. Genomic DNA (2 ng), 2x Go-taq 
Master Mix (5 μL), as well as 1 μL primer pair mix (T7: 5’- TAATACGACTCACTATAGGG-
3; hOCT1-REV: 5’- TGAAGGCCATCTGGTACATG -3’) were added together to a final 
volume of 20 µL and run in a thermocycler: initial denaturation at 95°C for 5 min, followed 
by 30 cycles of: denaturation at 95°C for 2 min, annealing at 50-52°C for 30 seconds, and 
elongation at 72°C for 30 seconds. Final elongation step at 72°C for 5 min and held at 
4°C. PCR products were loaded into a 1% agarose gel for separation using 
electrophoresis at 120 V for 60 min and visualized by UV light following ethidium bromide 
staining. 
4.B.8  Green fluorescent protein (GFP) plasmid construction 
To make the hOCT1-GFP fusion construct, the full length hOCT1 cDNA fragment 
was removed from the isolated library clone, pcDNA3/hOCT1, using the restriction 
enzymes Kpn I and Xba I. The fragment was gel isolated and ligated into the pEGFP-C1 
vector in frame at the carboxyl terminal end of GFP forming the plasmid pEGFP-
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C1/hOCT1, where “E” denotes “enhanced”. Plasmid construction was performed 
commercially (GenScript, Picataway, NJ). The lyophilized GFP plasmid construct, was 
resuspended and diluted in TE pH 8, transformed into DH5-alpha cells and DNA extracted 
using the Qiagen miniprep kit. The construct was confirmed by DNA sequencing. Non-
functional hOCT1 mutants were reproduced in the hOCT1-GFP construct using the 
original primers (Table 4.1) and the QuikChange Lightning site-directed mutagenesis kit.  
4.B.9  Microscopic imaging  
An Olympus IX-70 inverted microscope fit with a 12-bit camera was used to 
capture phase contrast and fluorescent images (Olympus, Melville, NY). Fluorescent 
images were taken with two second exposures using a 595 nm dichroic long pass filter 
(Chroma, Rockingham, VT) illuminated by a mercury arc lamp. The images were 
processed using Olympus Microsuite v.5. Confocal fluorescent images were obtained at 
the VCU Microscope Core facility using a Zeiss LSM 710 Axio Observer inverted laser 
scanning confocal microscope fitted with a 63x oil immersion objective. Images were 
collected by illuminating samples with a blue diode laser at 405 nm. Images were 
processed using Zeiss ZEN 2 Blue edition software (Oberkochen, Germany). 
4.B.10  Statistics 
The data plots were presented as means ± SD. Dose response curve (Km estimate) 
data were reported as mean ± SE for at least n = 3. Km estimates were fit based on the 
equation: V0 = Vmax * [S] / (Km + [S]). One-way ANOVA with post-hoc Dunnett’s test was 
used to evaluate differences compared to a single control where indicated. Statistical 
calculations were performed using Prism 5.0 (GraphPad Software, Inc., San Diego, CA). 
A difference was deemed statistically significant if p < 0.05.  
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4.C RESULTS 
4.C.1 Identification of a hOCT1 model 
The hOCT1 peptide sequence (Uniprot ID: O15245) was aligned with the PiPT 
template sequence (PDB ID: 4J05) (Figure 4.2) as input for the program MODELLER to 
generate 100 initial hOCT1 homology models. Analysis of the initial 100 models identified 
a single large cavity in the central region of the transporter as a potential binding pocket. 
MPP+ was subsequently docked in this region. After docking MPP+ into the generated 
hOCT1 models, the most favorable interaction model was selected based on three main 
criteria: GOLD docking score, DOPE score, and the total number of clusters. 
The genetic optimized ligand docking (GOLD) scoring is essentially a method to 
quantify which poses generated for a particular ligand are most likely to occur based on 
the interactions present within the transporter. GOLD scores for the top ten most 
favorable docked poses of MPP+ in the binding pocket of the hOCT1 models (ranging 
from 58.52 to 64.5) were ranked (Table 4.2). Amongst this select group, the top four 
model’s GOLD scores had a difference of 1.85 between them, thus were considered to 
be virtually identical. The difference between the top and fifth ranked model was 
increasingly larger (2.72). The discrete optimized protein energy (DOPE) score accounts 
for the shape of native structures which in turn helps to evaluate the quality of the whole 
protein structure. The DOPE scores for the top ten models ranged between -48,992 and  
-47,382 (Table 4.2). Additionally, the number of homology models which contained a 
given substrate pose (number of clusters) was also accounted for in model selection. The 
greater the number of models that have a particular substrate pose docked, the higher 
the likelihood that the specific pose occurs within the binding pocket. Out of the top 10 
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models, models 35 and 47 had the highest number of clusters (12 and 8 clusters, 
respectively), while the rest had 5 or less. Among the top four ranked GOLD score 
models, model 35 stood out as having the lowest DOPE score (-48,141; fifth lowest DOPE 
score overall) in conjunction with the highest number of clusters (12). Taken together, 
these three selection criteria indicate model 35 as the most favorable docked model and 
thus it was selected for subsequent studies. The generated tertiary structure for model 35 
with MPP+ docked in the hypothesized binding pocket is shown in Figure 4.3. The docked 
hOCT1 model shows MPP+ residing inside a large central cavity of the 12-membrane 
spanning alpha helical domains. 
Ramachandran plots were utilized as a method for determining and visualizing 
“allowed regions” for the backbone dihedral angles that make up amino acids in the 
generated model. For the amino acids that made up our selected hOCT1 model, 90.0% 
were in the most favored regions, 7.3% were in the additionally allowed region, and only 
2.7% were in the generously allowed and disallowed regions combined (Figure 4.4). The 
most favored regions category was considered high enough to support the selected 
hOCT1 model as acceptable. 
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Figure 4.2 Sequence alignment of PiPT and hOCT1.  
 
The alignment was constructed with ClustalX, followed by manually refining gaps based 
on the transmembrane regions observed in the PiPT crystal structure and predicted for 
hOCT1 using Phobius, a topology prediction algorithm. Residues were truncated for the 
large extracellular and intracellular loop between transmembrane domain 1 and 2 (TMD 
1 and 2) and between TMD 6 and 7 of PiPT and hOCT1, respectively. The 
transmembrane domains in the hOCT1 model and PiPT tertiary structure are shaded. “*” 
indicates exact sequence match, “:” indicates high sequence similarity, “.” indicates low 
sequence similarity 
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Table 4.2 Summary of hOCT1 model evaluation scores. 
GOLD Rank Model ID GOLD score DOPE Score 
No. of 
Clusters 
1 93 64.5 -47779.43359 5 
2 22 63.65 -47533.55859 1 
3 35 63.07 -48141.65625 12 
4 100 62.65 -48001.56641 3 
5 91 61.78 -48538.58984 3 
6 47 60.58 -48042.83594 8 
7 85 60.31 -47898.90625 1 
8 46 60.21 -48336.22656 2 
9 80 58.99 -47382.37891 1 
10 73 58.85 -48217.75 2 
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Figure 4.3 hOCT1 homology model.  
 
The generated 3-D molecular structure of hOCT1 (ribbons) is shown with MPP+ (space-filled) positioned in the putative 
binding pocket viewed from (A) profile and (B) top-down angles.  
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Figure 4.4 Ramachandran plot for hOCT1 homology model. 
Phi and psi indicate backbone conformation dihedral angles of amino acid residues, 
representing the rotations of a polypeptide main chain N-Cα and Cα-C bonds. Amino 
acids are displayed in different regions: most favored region (red), additional allowed 
region (yellow), generously allowed region (light yellow), and disallowed region (white). 
Residues depicted in red squares are in the generously allowed and disallowed regions. 
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4.C.2 Identifying amino acid residues important for MPP+ hOCT1 interaction 
Several amino acids were identified that made up the binding pocket (within the 
designated 5 Å radius of the substrate) for docked MPP+ in the selected hOCT1 model. 
The identified amino acid residues were found in several different TMDs that came 
together in the central area forming a large distinct cavity of the transporter—TMD 1: 
Trp16; TMD 5: Ile238, Gln241, Met242, Phe244, Thr245, Val246; TMD 7: Trp354, 
Asp357, Ser358, Tyr361, Gln362; TMD 8: Glu386, Ile387, Ala390; TMD 10: Ile444, 
Gln447, Ile449, Cys473 (Figure 4.5). Within the proposed binding pocket, five amino acids 
were identified (Gln241, Thr245, Phe244, Tyr361, and Gln447) as potential candidates 
critical for transporter-MPP+ binding interactions. Hydrophobic interactions were found 
between MPP+ and amino acid residues Gln241, Thr245, and Glu447, and one of the 
aromatic rings of MPP+ was recognized as forming edge-face-pi and pi-stacking 
interactions with Phe244 and Tyr361, respectively (Figure 4.6 and Table 4.3).  
To further evaluate the generated in silico hOCT1 model, known substrates with 
disparate structures were optimized and docked into the population of 100 models to 
determine the presence of alternative and/or additional critical amino acid residues in the 
binding pocket(s). The process involved with selecting the most favorable model for 
MPP+, was repeated for each docked substrate. Amino acids identified with the greatest 
overlap across the different docked compounds were Phe244, Asp357, Tyr361, and 
Gln447 (Figure 4.7 and Table 4.3). There were several amino acids identified that were 
also unique to particular compounds including Thr245 for MPP+; Trp16, Asn156, Phe159, 
and Asp474 for cimetidine; Gln20 for epinephrine; Leu23 for quinine; Ser358 for 
serotonin; and Ile449 for TPA.   
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Figure 4.5 3-D rendering of putative binding pocket of hOCT1 with docked MPP+. 
Amino acid side chains (white) comprising the binding pocket surrounding the substrate MPP+ (orange) is shown viewed 
from (A) profile and (B) top-down angles. 
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Figure 4.6 Structure of hOCT1 with MPP+ docked. 
 
The docked substrate (MPP+, orange) and the amino acids (white side chains) is shown 
localized in the predicted substrate binding pocket of hOCT1.  
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Table 4.3 hOCT1 docking interaction summary. 
Substrate Amino Acid Sequence position Bond Interaction TMD 
MPP+ Gln 241 Hydrophobic 5 
 Phe 244 Edge Face pi 5 
 Thr 245 Hydrophobic 5 
 Tyr 361 Pi-stack 7 
 Gln 447 Hydrophobic 10 
Cimetidine Trp  16 Hydrophobic 1 
 Asn 156 H-bond 2 
 Phe 159 Pi-stacking 2 
 Trp 217 Hydrophobic 4 
 Phe 244 Hydrophobic 5 
 Asp 357 H-bond (salt bridge) 7 
 Tyr 361 Pi-stacking 7 
 Gln 362 H-bond 7 
 Asp 474 H-bond (salt bridge) 11 
Epinephrine Gln 20 H-bond 1 
 Phe 244 Edge-face pi 5 
 Asp 357 H-bond 7 
 Tyr 361 Pi-stacking 7 
 Gln 447 Hydrophobic 10 
 Cys 450 Hydrophobic 10 
Metformin Phe 244 Edge-face pi 5 
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 Trp 354 Hydrophobic 7 
 Asp 357 H-bond (salt bridge) 7 
 Tyr 361 Pi-stack 7 
 Gln 447 Hydrophobic 10 
 Cys 473 Hydrophobic 10 
Quinine Leu 23 Hydrophobic 1 
 Trp 217 Hydrophobic (weak) 4 
 Phe 244 Hydrophobic 5 
 Asp 357 H-bond  7 
 Tyr 361 Pi-stacking 7 
 Gln 447 H-bond  10 
 Cys 473 Hydrophobic 10 
Serotonin Gln 241 H-bond 5 
 Phe 244 Hydrophobic 5 
 Asp 357 H-bond 7 
 Ser 358 Hydrophobic 7 
 Tyr 361 Pi-stack 7 
 Gln 362 H-bond 7 
 Ile 444 Hydrophobic 10 
 Cys 473 H-bond 10 
TPA Phe 244 Hydrophobic 5 
 Asp 357 Ionic w/quaternary N 7 
 Tyr 361 Hydrophobic 7 
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 Ile 444 Hydrophobic 10 
 Gln 447 Hydrophobic 10 
 Ile 449 Hydrophobic 10 
  Cys 450 Hydrophobic 10 
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Figure 4.7 Known hOCT1 substrates docked into hOCT1 homology model. 
Known hOCT1 substrates (purple or orange) (A) cimetidine, (B) epinephrine, (C) metformin, (D) quinine, (E) serotonin, and 
(F) TPA, were docked into their respective favorable hOCT1 models. Proposed interactions of interactions are summarized 
in Table 4.3. 
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4.C.3 Substitution of hOCT1 amino acid residues in putative binding pocket 
We investigated the role of the predicted amino acids in hOCT1-MPP+ interactions 
through conservative and non-conservative amino acid substitutions introduced into the 
hOCT1 coding sequence to evaluate potential changes in hOCT1 function and affinity for 
MPP+. The pcDNA3/hOCT1 plasmid vector map is shown in Figure 4.8. The rationale for 
deciding each conservative and non-conservative amino acid substitution was based on 
a scheme developed by Bordo et al. which categorizes roughly equivalent amino acid 
residues based on their physicochemical properties of their side chains (Figure 4.9) [157]. 
Substitutions for residues deemed critical were Gln241Glu, Phe244Tyr, Thr245Ser, 
Tyr361Phe, and Gln447Glu (conservative); and Gln241Lys, Phe244Ser, Thr245Lys, 
Tyr361Ala, and Gln447Lys (non-conservative) (Tables 4.4, 4.5, and 4.6). Several 
attempts were made to generate the hOCT1 Tyr361Phe mutant. However, each time, the 
desired mutation was present as a tandem repeat, i.e., the entire target region 
incorporated into the mutation generating primers was duplicated in the final product. We 
were unable to resolve how or why this occurred. All successfully constructed hOCT1 
mutants were confirmed by DNA sequencing prior to generating stable cell lines. Figure 
4.10, depicts a representative DNA-oligonucleotide duplex and sequencing 
chromatogram in which CAA, coding for Gln447 in wildtype hOCT1, was changed to GAA, 
coding for the hOCT1 mutant Gln447Glu. 
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Figure 4.8 pcDNA3/hOCT1 vector map. 
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Figure 4.9 Suggested guidance for amino acid residue conservative substitution. 
Roughly equivalent amino acid residues categorized based on physiochemical properties into five subgroups.  
 
Diagram is an adapted figure from reference [157] 
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Table 4.4 Summary of hOCT1 residue substitutions. 
  Substitution 
Residue Conservative Non-Conservative 
Gln241 Glu Lys 
Phe244 Tyr Ser 
Thr245 Ser Lys 
Tyr361   Phea Ala 
Gln447 Glu Lys 
a Mutant was not able to be generated 
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Table 4.5 hOCT1-MPP+ interaction based conservative substitutions. 
Amino Acid Sequence position Codon Mutant Codon Substitution 
Gln 241 CAG GAG Gln → Glu 
Phe 244 TTC TAC Phe →Tyr 
Thr 245 ACG TCG Thr → Ser 
Tyr 361 TAT TTT Tyr → Phea 
Gln 447 CAA GAA Gln → Glu 
a mutant was not able to be generated 
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Table 4.6 hOCT1-MPP+ interaction based non-conservative substitutions. 
Amino Acid Sequence position Codon Mutant Codon Substitution 
Gln 241 CAG AAG Gln → Lys 
Phe 244 TTC TCC Phe →Ser 
Thr 245 ACG AAG Thr →Lys 
Tyr 361 TAT GCT Tyr → Ala 
Gln 447 CAA AAA Gln → Lys 
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Figure 4.10 Representative sequencing chromatogram for hOCT1 mutants. 
 
(A) DNA template-primer duplex for hOCT1 Q447E. Chromatogram for (B) hOCT1 
wildtype and (C) hOCT1 Q447E are shown with triplet codon corresponding to mutation 
site highlighted 
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4.C.4 Critical amino acid confirmation through kinetic assays 
In functional screening assays evaluating [3H] MPP+ transport (Figure 4.11), wild-
type hOCT1 demonstrated a 5-fold higher uptake of MPP+ compared to mock expressing 
(pcDNA3) background control cells (11.7 ± 4.9 pmol mg protein-1 10 min-1 vs. 2.4 ± 0.02 
pmol mg protein-1 10 min-1). Quinine (200 µM), a known inhibitor for OCTs, virtually 
abolished hOCT1 mediated MPP+ transport. Four non-conservative mutants, hOCT1 
Glu241Lys, Thr245Lys, Tyr361Ala, and Gln447Lys, resulted in a complete loss of MPP+ 
transport activity (Figure 4.11). All other mutants retained some level of transport activity 
and were subjected to saturation analysis in order to estimate Km (Figure 4.12, Table 4.7).  
The affinity of MPP+ determined for wildtype hOCT1 was comparable to values in 
prior studies (Km = 16.3 ± 3) [158]. When comparing the Km estimates for hOCT1 mutants 
against wildtype hOCT1, the non-conservative substitution Phe244Ser and the 
conservative substitution Thr245Ser resulted in a significant decrease in affinity for MPP+. 
The mutants Gln241Glu, Phe244Tyr, and Gln447Glu, all demonstrated no significant 
change in affinity for MPP+.  
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Figure 4.11 Functional screen of CHO-hOCT1 wild type and mutant expressing cell 
lines. 
 
CHO cells were treated with transport buffer containing 1 µM [3H] MPP+ (0.25 µCi/mL) in 
the absence or presence of inhibitor (quinine) for 10 min. Conservative and non-
conservative mutations appear above original amino acid position. Data shown as 
duplicate values ± SD. ** denotes p<0.01; *** denotes p<0.001; compared against wild 
type control by one-way ANOVA followed by post-hoc Dunnett’s t-test. 
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Figure 4.12 Representative dose response curves for wild type and mutant hOCT1. 
Michaelis-Menten kinetics of [3H] MPP+ transport (1–200 µM) for hOCT1 and hOCT1 
mutants in stably transfected CHO cells.  
.  
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Table 4.7 Summary of Km estimates for hOCT1 constructs. 
hOCT1 Transporter Km (µM) 
WT 16.3 ± 2.5 
Gln241Glu 18.2 ± 1.2 
Phe244Tyr 24 ± 0.32 
Phe244Ser 33.4 ± 5* 
Thr245Ser 37.4 ± 6.4* 
Gln447Glu 14.3 ± 2.6 
Mean Km estimates acquired from triplicate experiments ± SE.  
* denotes p < 0.05 compared against wild type control by one-way 
ANOVA followed by post-hoc Dunnett’s t-test. 
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4.C.5 Genomic integration of non-functional hOCT1 mutant constructs 
To eliminate failed genomic DNA integration as an explanation for the lack of 
transport activity in non-functional hOCT1 mutants, genomic DNA was extracted and PCR 
amplified using the primers T7 and hOCT1 REV, that flanked 5’ and 3’ ends of the hOCT1 
coding sequence of the pcDNA3 plasmid (hOCT1 amplicon ~1.7 kb). PCR products of 
the expected size (~1.7 kb) were obtained for wildtype hOCT1 and all hOCT1 mutants 
(Gln241Lys, Tyr361Ala, Thr245Lys, and Gln447Lys), while no product was observed for 
negative controls (water and pcDNA3) demonstrating that all hOCT1 plasmids had been 
successfully integrated (Figure 4.13).  
4.C.6 Membrane targeting of hOCT1-GFP fusion construct 
The full length hOCT1 cDNA fragment was gel isolated and ligated into vector 
pEGFP-C1 forming the plasmid pEGFP-C1/hOCT1 containing hOCT1 fused in frame to 
the carboxyl terminal of GFP (Figure 4.14). CHO cells expressing the hOCT1-GFP 
fusion construct showed strong fluorescence within the cytosol and lack of signal in the 
nucleus (Figure 4.15). This pattern is consistent with an intact GFP fusion construct 
versus expression of “free” GFP. However, no noticeable fluorescence at the plasma 
membrane was observed. Control transfections (lipofectamine only) showed no 
fluorescent signal (data not shown). In order to have a reference of the membrane 
localization of OCTs, MDCK cells stably transfected with a rat Oct2-GFP fusion 
construct from a previous study were grown and observed [159] (Figure 4.16). 
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Figure 4.13 PCR analysis of genomic DNA isolated from hOCT1 cell lines. 
Confirmation of successful genomic integration of mutant hOCT2 constructs that lacked 
transport activity. Lanes: (1) water, (2) pcDNA3, (3) hOCT1, (4) hOCT1 Gln241Lys, (5) 
hOCT1 Thr245Lys, (6) hOCT1 Tyr361Ala, (7) hOCT1 Gln447Lys 
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Figure 4.14 pEGFP-C1/hOCT1 fusion protein vector map. 
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Figure 4.15 Expression patterns of pEGFP-C1/hOCT1. 
CHO cells transfected with pEGFP-C1/hOCT1 were fixed, permeabilized, and mounted 
at 24 hours post transfection then viewed under confocal microscopy: (A) phase contrast, 
(B) GFP, (C) DAPI, and (D) merge. Scale bar = 20 µm 
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Figure 4.16 Expression of pEGFP-C3/rOct2 in MDCK cells. 
MDCK cells stably transfected with pEGFP-C3/rOct2 were thawed, grown in culture for 
48 hours, then observed by fluorescence microscopy (40x magnification). Observed cells 
were used in a study performed in reference [159] 
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4.D DISCUSSION 
The polyspecific nature of the OCTs make them prime targets for potentially 
unwarranted effects of drug-drug interactions. Any insight on the physiochemical nature 
of the substrate interactions for these transporters will undoubtedly serve to guide the 
prediction of such occurrences. The importance of understanding OCT-substrate 
interactions has recently garnered more attention. Several important studies have 
identified probable residues for OCT substrate interaction through the use of homology 
models based on the crystallized structures of the prokaryotic MFS transporters LacY or 
GlpT [143,146,148,153]. Their initial findings were helpful in establishing the usefulness 
of this relatively novel technique for the understanding of OCT transport, however, may 
be limited due to low sequence identities shared between the templates used and 
mammalian OCTs (~15%).  
Therefore, in the current study, homology models of the tertiary structure of hOCT1 
were generated using the known crystal structure of PiPT serving as the template. PiPT, 
also a member of the MFS, was chosen as the designated template due to a number of 
factors including its relative sequence homology to the hOCTs (~21% identical, 40% 
similar), eukaryotic origin (Piriformospora indica), and the fact that it was crystallized in 
the occluded state. The occluded conformation grants the transporter maximum binding 
interaction sites for bound ligands. After docking MPP+ into the generated hOCT1 models, 
amino acid residues were identified that formed the putative binding pocket (within a 5 Å 
radius surrounding the substrate) (Figure 4.6). This approach required that several 
assumptions be made during the in silico model building process including that adequate 
structural similarity exists between the crystallized tertiary structure of PiPT and hOCT1 
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and that the presence of water molecules in the occluded binding pocket was negligible 
and therefore not considered during the docking analysis. All models were generated 
based on PiPT and the hOCT1 protein sequence with transmembrane domains globally 
energy minimized. Amino acid residues deemed “critical” for hOCT1-MPP+ binding 
interactions were identified in silico based on substrate proximity and interaction type 
(Table 4.3).  
Within the proposed binding pocket, hydrophobic interactions were identified 
between MPP+ and amino acid residues Gln241, Thr245, and Glu447, and one of the 
aromatic rings of MPP+ was found to be involved in edge-face pi and pi-stacking 
interactions with Phe244 and Tyr361, respectively. Subsequently, stably transfected CHO 
cells expressing hOCT1 mutants were established and utilized for a series of in vitro 
kinetic assays to confirm their role in substrate binding. From the functional screening 
study, transport activity of MPP+ was absent in the non-conservative substitution of 
Gln241, Thr245, Tyr361, and Gln447 (Figure 4.11). All conservative substituted mutants, 
and one non-conservative substitution retained transport function (Phe244). The MPP+ 
docked hOCT1 model predicted strong interactions for Phe244 and Tyr361 (edge-face pi 
and pi-pi stacking, respectively). The retained transport function for both mutants of 
Phe244 contradicted the model’s prediction. Loss of transport function by the 
conservative Tyr361Ala mutation suggested that this residue may be a critical site for 
substrate binding. This result correlates with the MPP+ docking data where Tyr361 was 
predicted to participate in the strongest substrate interactions (pi-pi stacking). However, 
in contrast to hOCT2, we were unable to isolate the conservative hOCT1 Tyr361Phe 
mutant. Thus, whether or not a similar possibility as observed for hOCT2 exists for hOCT1 
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for the aromatic hydroxyl group to mediate additional important interactions with other 
residues within the binding pocket beyond pi-pi stacking with MPP+ and, thus, playing a 
significant role in forming the structure of the binding pocket, is unknown. Evaluating the 
transport function for the conservative substituted mutant of Tyr361 (mutant was unable 
to be constructed) would provide stronger support as a critical residue for MPP+ 
interaction.  For hOCT1 mutants retaining MPP+ transport function, Phe244Ser and 
Thr245Ser displayed significantly decreased substrate affinity (Table 4.7). In turn, it is 
plausible to suggest that Phe244Ser and Thr245Ser are important sites for MPP+ 
interaction. Future studies involving the generation of a Phe244Ser/Thr245Ser double 
mutant could provide additional evidence to support their importance for substrate 
interaction. These preliminary findings suggest that Glu241, Phe244, Thr245, Tyr361, and 
Gln447 are the leading candidate residues that may be involved in hOCT1-MPP+ 
interactions. Among these, Thr245 holds the strongest case since its conservative 
substituted mutant had significantly attenuated affinity and its non-conservative mutant 
demonstrated a complete loss of activity for the transport of MPP+.  
The complete loss of MPP+ transport activity by hOCT1 mutants (Gln241Lys, 
Thr245Lys, Tyr361Ala, and GLn447Lys) may be due to several of the following factors. 
The amino acid could be largely responsible for MPP+ interactions such that when 
mutated will lead to the loss of transport and/or a change in the overall conformation of 
the binding pocket. Alternatively, there could have been issues during the transfection 
process leading to the absence of cDNA integration into the genome. Another possibility 
is that the amino acid may be critical for the structural integrity or trafficking of the 
transporter within the cell. If this were the case, mutations at this residue could lead to 
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protein misfolding that is subsequently degraded rather than integrating into the cellular 
membrane following its translation.  
Genomic integration of intact cDNA for hOCT1 mutants was confirmed by PCR 
and gel electrophoresis (Figure 4.13) thus ruling out failed transfection. In order to confirm 
that inactive mutant hOCT1 transporters were translated and inserted into the plasma 
membranes of transfected mammalian cell lines, a hOCT1-GFP fusion construct was 
made by fusing the coding sequence of hOCT1 to the C-terminus of GFP and transfected 
into CHO cells. Plasma membrane targeting was achieved in earlier studies using a 
similarly constructed GFP fusion construct for rat Oat1 and rat Oct2 transfected into 
MDCK cells [159,160]. In the current study, however, plasma membrane targeting was 
not observed in CHO cells transiently transfected with the wildtype hOCT1-GFP fusion 
construct. Instead a consistent pattern of fluorescence in the cytosol was noticed. The 
discrepancy in what was observed compared to the prior studies perhaps may be due to 
differences associated with the cell line used (MDCK vs CHO cells). A future study 
involving the transfection of our pEGFP-hOCT1 fusion construct into MDCK cells should 
be considered.  
For the analysis of docking known substrates with a diverse array of structural 
features into hOCT1 homology models, amino acids identified were unique to some 
substrates and shared for others (Table 4.3). For example, Glu 447 was among the group 
of residues that was shared across a diverse group of substrates which included MPP+, 
epinephrine, metformin, quinine, and TPA. The conserved residue in rabbit Oct2 (also at 
position 447) was identified as a critical site for mediating TEA transport which was 
subsequently confirmed in a rabbit Oct2 homology model on GlpT [153]. Under 
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physiological conditions, the acidic side chain present in Glu477 may be anchoring the 
transport of positively charged compounds. Cys451, identified in a previous study as a 
residue important for mediating choline transport by rabbit Oct1 and verified through 
homology models based on the solved structure of LacY [144], was also identified in the 
present study (Cys450) for interacting with epinephrine and TPA. This observation is 
consistent chemically since both choline and TPA both contain a quaternary amine. TPA 
was also predicted to interact with Cys473 in the hOCT1 homology model in the current 
study. In a different study, the conserved residue, Cys474, in hOCT2 was demonstrated 
to mediate TEA transport and verified by a hOCT2 homology model generated based on 
the crystallized tertiary structure of GlpT [146]. Both TEA and TPA also share a similar 
quaternary nitrogen backbone in their chemical structures which may explain their shared 
interaction with cysteine in this particular binding region in hOCT transporters. From these 
observations, our model suggests that there may be one binding pocket along the central 
cavity of hOCT1. Within this binding pocket, there may be a core set of amino acids that 
interact with most substrates, in conjunction with additional substrate-specific amino acids 
that that accommodate structurally diverse substrates. Additional in vitro work involving 
transporter mutagenesis experiments and subsequent kinetic analysis for each substrate 
would be necessary to support the preliminary in silico findings. 
From the in silico hOCT1 modeling and subsequent in vitro kinetic work in the 
current study, TMDs 5, 7, and 10 were the regions that contained the amino acids 
predicted to interact with MPP+. Other OCT-substrate interaction studies identified 
important residues in TMDs 4, 10, and 11 [124,125,143,146,148,153]. Several factors 
should be considered that could help delineate these apparent disparate observations. 
 
 
137 
 
OCT models generated from different species of rodents were evaluated in the earlier 
interaction studies, thus species differences could account for the variations of identified 
residues. Interaction studies were conducted on different substrates. The current work 
generated hOCT1 models which were docked with MPP+, while the other studies on rat 
and rabbit docked TEA and choline. As determined in the analysis involving docking 
known hOCT1 substrates, amino acid residues critical for interaction may be unique to 
each compound. Given the diverse substrate specificity of hOCT1, this result was not 
unexpected. In prior homology model studies, rodent Oct1 was modeled based on the 
tertiary structures of LacY and GlpT. The differences in observations may have been 
anticipated since the models constructed in the present study were generated by PiPT, a 
transporter with higher sequence identity with the mammalian OCTs. And finally, there is 
the fact LacY and GlpT were crystallized in the inward conformation which differs from 
the occluded state structure solved for PiPT. As such, amino acids that are accessible to 
interacting substrates during the in silico docking steps may vary.  
In summary, a homology model for hOCT1 based on the solved structure of PiPT 
was successfully constructed. Through the docking of MPP+ into the generated homology 
models, important residues associated with substrate binding interactions as well as the 
putative binding pocket were identified. Identified amino acids were further investigated 
in subsequent in vitro mutagenesis studies and kinetic analysis. The findings of the 
current study suggest that many substrates share both overlapping and unique interaction 
sites. Although differences in the identified important residues were recognized through 
comparisons with other similar studies, there were a few that were shared. Future work, 
particularly confirming successful targeting of the membrane for non-functional hOCT1 
 
 
138 
 
mutants, will be required to strengthen the current claims. Findings from the current study 
certainly lays down the foundation for future work that could ultimately offer important 
direction for optimizing drug design as well as mitigating the rates of OCT related drug-
drug interactions.  
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CHAPTER 5 
 
COMPARISON OF SUBSTRATE BINDING INTERACTIONS BETWEEN HUMAN 
ORGANIC CATION TRANSPORTERS 1, 2, AND 3 
 
In human, organic cation transporters play a critical role in mediating the transport 
of a vast array of endogenous and exogenous compounds across barrier epithelia of the 
major distribution and eliminating organ systems; namely the intestine, liver, and kidney 
[1]. As such, OCTs, in particular OCT1, 2, and 3, have garnered additional attention from 
investigators hoping to better understand their roles in drug disposition and elimination. 
To date, due to the lack of a solved crystal structure, very little is known about the three-
dimensional structure of human OCTs or substrate/protein interactions involved in their 
transport. Some early efforts involving the use of secondary structure information to 
determine important binding sites of the rat Oct1 and 2 have been conducted [124,125]. 
Since then, newer strategies involving computational homology modeling have been 
conducted to assist in forming more robust predictions as well as helping guide 
mutagenesis experiments [128,132]. In the current study, potentially critical amino acid 
residues important for transporter-substrate interactions were identified for human OCT1 
and OCT2 through in silico molecular modeling techniques, paired with in vitro 
mutagenesis and kinetic transporter experiments.  
Tertiary homology models for hOCT1 and hOCT2 were successfully generated 
using the recently crystallized MFS transporter, PiPT, as template. The generated models 
were in silico docked with the prototypical OCT substrate MPP+. The most favorable 
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docked MPP+ model was selected based on a series of computational validation methods 
and subsequently used to predict several potentially important sites for substrate-
transporter interaction. This information was used to guide in vitro mutagenesis studies 
and kinetic experiments. This experimental strategy was carefully implemented for the 
elucidation of residues in both hOCT1 and hOCT2.  
From the results obtained from the functional screening assay, four non-
conservative mutations of hOCT1 (Glu241Lys, Thr245Lys, Tyr361Ala, and Gln447Lys) 
resulted in a complete loss of MPP+ transport activity (Figure 4.11). For hOCT2, this was 
the case for two non-conservative mutants, hOCT2 Glu242Lys and Tyr362Ala, and one 
conservative mutant hOCT2 Tyr362Phe (Figure 3.11). In a different study conducted in 
hOCT3, two conservative mutants, (Trp358Phe and Asp475Glu) and two non-
conservative mutants (Val40Ala and Trp358Ala) demonstrated a loss of MPP+ transport 
activity [164]. Across OCT1-3, the only residue overlap for these sets of experiments was 
observed for hOCT1 and hOCT2 (Tyr361/Tyr362 and Gln241/Gln242). The Tyr residue 
at these positions in particular were both predicted to participate in the strongest 
interactions with MPP+ in their respective homology models (pi-pi stacking) which 
correlates with this functional result acquired in vitro. Alternatively, the loss of MPP+ 
transport activity for the conservative hOCT2 mutant, Tyr362Phe, suggests that the 
hydroxyl group in Tyr362 may be interacting with other residues and thus could be a major 
contributor to the tertiary structure of the binding pocket. Similar observations were not 
able to be made at the conserved site in hOCT1 (Tyr361) since the generation of the 
Tyr361Phe mutant was unsuccessful. The most critically involved amino acid in hOCT3-
MPP+ interactions was Trp358, where both conservative and non-conservative 
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substitutions yielded a loss of substrate transport [164]. Taken together, these results 
suggest that hOCT1 and hOCT2 share a similar binding pocket with one another, 
whereas, the binding pocket for hOCT3 appears unique.  
For mutants that retained transport activity, saturation analysis was conducted to 
evaluate potential changes in transporter affinity for MPP+. When compared with wildtype 
(Km = 16.3 ± 2.5), hOCT1 mutants that were observed to have a significant decrease in 
transporter affinity was the non-conservative substitution Phe244Ser and the 
conservative substitution Thr245Ser (Km = 33.4 ± 5 and 37.4 ± 6.4, respectively) (Table 
4.7). In hOCT2, only the non-conservative substitution Tyr245Ala resulted in a significant 
change in affinity for MPP+ (Km = 36.5 ± 5) (Table 3.7). In hOCT3, the conservative mutant 
Val40Leu and non-conservative mutants Phe36Ala, Glu451Ala, and the double mutant 
Val40Leu/Glu451Ala showed a significant change in substrate affinity [164]. The double 
mutant in hOCT3 confirmed Val40 and Glu451 importance in binding interactions since 
the affinity was lowered significantly more when both mutations were changed compared 
to each mutant changed individually.  
The homology models for hOCT1, 2, and 3 were further evaluated by docking 
known substrates with disparate structures into each population of 100 models to 
determine the presence of alternative and/or additional critical amino acid residues in the 
binding pocket(s). Epinephrine, metformin, serotonin, and TPA were docked into all three 
OCT models. Additional compounds, cimetidine and quinine, were docked into hOCT1 
and hOCT2. Several amino acids, which made up the “core binding residues” based on 
their high frequency of overlap across the different docked compounds for each 
transporter were identified: hOCT1: Phe244, Asp357, Tyr361, and GLn447 (Table 5.1); 
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hOCT2: Tyr245, Ser358, Tyr362, and Glu448 (Table 5.2); and hOCT3: Val40, Met248, 
Trp358, and Asp478 (Table 5.3). Amongst this list across hOCT1-3, aspartic acids and 
glutamic acids, particularly in TMDs 10 and 11, seem to be important for substrate 
interactions. These amino acids with acidic side chains, under physiologic conditions (pH 
7.4) are likely to anchor cations as they translocate across the membrane through the 
transporter.  
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Table 5.1 hOCT1 substrate docking summarya. 
Residue MPP+ Cimetidine Epinephrine Metformin Quinine 5-HT TPA 
Trp16   x           
Gln20 
  
x 
    
Leu23 
    
x 
  
Asn156 
 
x 
     
Phe159 
 
x 
     
Trp217 
 
x 
  
x 
  
Gln241 x 
    
x 
 
Phe244 x x x x x x x 
Thr245 x 
      
Trp354 
   
x 
   
Asp357 
 
x x x x x x 
Ser358 
     
x 
 
Tyr361 x x x x x x x 
Gln362 
 
x 
   
x 
 
Ile444 
     
x x 
Gln447 x 
 
x x x 
 
x 
Ile449 
      
x 
Cys450 
  
x 
   
x 
Cys473 
   
x x x 
 
Asp474   x           
a Data acquired from Figure 4.7 and Table 4.3 
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Table 5.2 hOCT2 substrate docking summarya. 
Residue MPP+ Cimetidine Epinephrine Metformin Quinine 5-HT TPA 
Phe24         x   x 
Asn157 
 
x 
  
x 
  
Phe160 
    
x 
 
x 
Gln242 x 
   
x 
  
Tyr245 x x x 
 
x x x 
Thr246 x 
      
Ser358 
 
x x x 
 
x 
 
Tyr362 x x x x x x 
 
Gln363 
     
x 
 
Glu387 
     
x 
 
Glu448 x x x x 
 
x 
 
Cys451 
     
x 
 
Cys474 
      
x 
Asp475   x           
a Data acquired from Figure 3.7 and Table 3.3 
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a Data acquired from reference [164] 
  
Table 5.3 hOCT3 substrate docking summarya. 
Residue MPP+ Epinephrine Metformin 5-HT TPA 
Phe36 x x       
Val40 x x 
 
x 
 
Asn162 
 
x 
 
x 
 
Met248 
 
x x x 
 
Trp358 x 
 
x 
 
x 
Gln366 
 
x 
   
Glu451 x 
    
Ser474 
  
x 
  
Cys477 
 
x 
   
Asp478 x x x x   
 
 
146 
 
It was previously reported that transport activity was completely abolished by an 
Asp478 mutation in hOCT3 [164]. Through sequence alignment, the homologous site in 
hOCT2 was identified as Asp475. The analogous conservative substitution of hOCT2 
Asp475 was generated and stably expressed in CHO cells for functional screening 
studies. In stark contrast to the hOCT3 results, the conserved mutant in hOCT2 showed 
no difference from wild-type hOCT2 in transport activity of MPP+ (data not shown). This 
finding was supported by our hOCT2 in silico model wherein Asp475 was located outside 
of the binding pocket and not predicted to interact with MPP+. The difference in transporter 
function and affinity observed between hOCT3 Asp478Glu and hOCT2 Asp475Glu 
suggests that the critical residues for MPP+-transporter interaction may vary depending 
on the OCT paralog even for the same substrate and supports the contention that the 
binding pocket in hOCT3 is distinct from that for hOCT1 and hOCT2. Despite a high 
degree of sequence similarity (70%) and identity (51%) between hOCT2 and hOCT3, the 
conserved aspartic acid residue (position 475 in hOCT2 and position 478 in hOCT3) 
previously demonstrated to be essential for MPP+ interaction with hOCT3 appears to 
exert no influence on MPP+ interaction with hOCT2. 
The whole story detailing the most accurate depiction of the nature of the 
physiochemical interactions for hOCT1, 2, and 3 is far from complete. The utilization of 
homology models with the most closely related available transporter templates is currently 
the leading strategy in achieving the overarching goal of the elucidation of the amino acids 
critical for protein-ligand interaction. A comprehensive list of future work is necessary for 
reaching stronger conclusions on the current hOCT interaction studies. This includes 
additional studies to resolve the issue related to evaluating transporter targeting to plasma 
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membrane. Acquiring this information will significantly dictate the validity of the claims 
made for the hOCT non-functional mutants. Given the lack of specificity of commercial 
antibodies tested and the inconclusive results of the GFP fusion construct studies, an 
alternative approach could be the addition of a polypeptide tag with a known commercial 
antibody (e.g. FLAG, c-Myc, 6x His) to the hOCT proteins. The establishment of double 
mutants for hOCT1 and 2 will be helpful in providing additional valuable kinetic information 
for functioning single mutants showing attenuated affinity. This analysis will in turn 
determine any potential changes in double-mutant affinity for MPP+ which could offer 
further insight to the significance for specific residues involved with transporter-substrate 
interaction. Finally, the additional amino acid residues that were identified in the analysis 
of docking known structurally disparate hOCT substrates will need to be further 
investigated. This can be conducted through the generation of stably transfect mutants 
based on the additional residues identified and subsequent kinetic transport analysis of 
the structurally disparate substrates.  
The data collected from the current study in addition to the proposed future 
experiments will bring forward new information regarding the substrate binding site of 
hOCT1-3 of which will provide the necessary clues for their underlying mechanism of 
transport. The identified amino acid residues that contribute to substrate binding may offer 
useful insight to the transporter-substrate recognition by other members of the SLC22 
family owing to their similarities in sequence homology. In the end, unveiling the critical 
residues for hOCT1-3 will steer the future of drug design by improving safety/efficacy as 
well as strengthening our predictions that eventually could lead to reductions in the rates 
of harmful drug-drug interactions.  
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